protocolSection,resultsSection,documentSection,derivedSection,hasResults
"{'identificationModule': {'nctId': 'NCT02838420', 'orgStudyIdInfo': {'id': 'YO29449'}, 'organization': {'fullName': 'Hoffmann-La Roche', 'class': 'INDUSTRY'}, 'briefTitle': 'A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)', 'officialTitle': 'Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer'}, 'statusModule': {'statusVerifiedDate': '2025-09', 'overallStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2016-08-03', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-05-31', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2016-07-18', 'studyFirstSubmitQcDate': '2016-07-18', 'studyFirstPostDateStruct': {'date': '2016-07-20', 'type': 'ESTIMATED'}, 'resultsFirstSubmitDate': '2019-05-29', 'resultsFirstSubmitQcDate': '2019-07-09', 'resultsFirstPostDateStruct': {'date': '2019-07-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-09-17', 'lastUpdatePostDateStruct': {'date': '2025-10-01', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Hoffmann-La Roche', 'class': 'INDUSTRY'}}, 'oversightModule': {'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of alectinib versus crizotinib and to evaluate the pharmacokinetics of alectinib in asian participants with treatment-naive ALK-positive advanced NSCLC. Participants will be randomized 2:1 into one of the two treatment groups to receive either alectinib (600 milligrams \\[mg\\] twice daily \\[BID\\]) or crizotinib (250 mg BID) orally, respectively.'}, 'conditionsModule': {'conditions': ['Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 187, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Alectinib', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death.', 'interventionNames': ['Drug: Alectinib']}, {'label': 'Crizotinib', 'type': 'ACTIVE_COMPARATOR', 'description': 'Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death.', 'interventionNames': ['Drug: Crizotinib']}], 'interventions': [{'type': 'DRUG', 'name': 'Alectinib', 'description': 'Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.', 'armGroupLabels': ['Alectinib'], 'otherNames': ['RO5424802']}, {'type': 'DRUG', 'name': 'Crizotinib', 'description': 'Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.', 'armGroupLabels': ['Crizotinib']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1', 'description': 'PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by the investigators, or to death from any cause, whichever occurred first.', 'timeFrame': 'From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months)'}], 'secondaryOutcomes': [{'measure': 'PFS as Determined by Independent Review Committee (IRC) Using RECIST v1.1', 'description': 'PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by an independent review committee, or to death from any cause, whichever occurred first.', 'timeFrame': 'Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months)'}, {'measure': 'Percentage of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Using RECIST v1.1', 'timeFrame': 'Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months)'}, {'measure': 'Time to Progression of Disease in the CNS as Determined by IRC Using RECIST v1.1', 'timeFrame': 'Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months)'}, {'measure': 'Time to Progression of Disease in the CNS as Determined by IRC Using Response Assessment in Neuro-Oncology (RANO)', 'timeFrame': 'Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months)'}, {'measure': 'Duration of Response (DOR) Assessed by Investigator Using RECIST v1.1', 'timeFrame': 'Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months)'}, {'measure': 'Overall Survival Time', 'timeFrame': 'Baseline, until death (up to overall period of approximately 40 months)'}, {'measure': 'Percentage of Participants With Non-serious Adverse Events and Serious Adverse Events', 'description': 'An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.', 'timeFrame': 'Up to overall period of approximately 40 months'}, {'measure': 'Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Core (QLQ-C30) Score', 'timeFrame': 'Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months)'}, {'measure': 'Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Lung Cancer Module (QLQ-LC13) Score', 'timeFrame': 'Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months)'}, {'measure': 'Area Under the Plasma Concentration-time Curve (AUC) of Alectinib and Its Metabolite', 'description': 'AUC was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time.', 'timeFrame': 'Baseline and Week 4 predose (within 2 hours before administration of study drug)'}, {'measure': 'Maximum Plasma Concentration Observed (Cmax) of Alectinib and Its Metabolite', 'description': 'Cmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time.', 'timeFrame': 'Baseline and Week 4 predose (within 2 hours before administration of study drug)'}, {'measure': 'Time to Cmax (Tmax) of Alectinib and Its Metabolite', 'description': 'Tmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time.', 'timeFrame': 'Baseline and Week 4 predose (within 2 hours before administration of study drug)'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana immunohistochemistry (IHC) test. Sufficient tumor tissue available to perform ALK IHC is required. Ventana IHC testing will be performed at the designated central laboratory\n* Life expectancy of at least 12 weeks\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2\n* No history of receiving systemic treatment for advanced, recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC\n* Adequate hematologic function: Platelet count greater than equal to (\\>=) 100×10\\^9 per liter (/L); absolute neutrophil count (ANC) \\>=1500 cells per microliter (cells/mcL); hemoglobin\\>=9.0 grams per deciliter (g/dL)\n* Adequate renal function: an estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) formula of \\>=45 milliliters per minute per 1.73 square meter\n* Participants must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before receiving the first dose of study treatment\n* Measurable disease (by Response Evaluation Criteria in Solid Tumors version 1.1 \\[RECIST v1.1\\]) before administration of study treatment\n* Previous brain or leptomeningeal metastases are allowed if the participant is asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic central nervous system (CNS) lesions may be treated at the discretion of the investigator as per local clinical practice. If participant has neurological symptoms or signs because of CNS metastasis, the participant must complete whole-brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed \\>=14 days before enrollment and disease must be clinically stable\n* For all females of childbearing potential, a negative serum pregnancy test result must be obtained within 3 days prior to starting study treatment\n* For women who are not postmenopausal (\\>=12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus), agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of \\<1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of contraceptive methods with a failure rate of \\<1% per year include tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of \\<1% per year. Barrier methods must always be supplemented with the use of a spermicide\n* For men, agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \\<1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception\n\nExclusion Criteria:\n\n* A malignancy within the previous 3 years (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in progression-free survival (PFS) or overall survival (OS) for the current NSCLC)\n* Any GI disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post-major bowel resection\n* Liver disease characterized by:\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than (\\>) 3× the upper limit of normal (ULN; \\>=5×ULN for participants with concurrent liver metastases) confirmed on two consecutive measurements; or\n* Impaired excretory function (e.g., hyperbilirubinemia), synthetic function, or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices; or\n* Acute viral or active autoimmune, alcoholic, or other types of hepatitis\n* National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 Grade 3 or higher toxicities because of any previous therapy (e.g., radiotherapy) (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication\n* History of organ transplant\n* Co-administration of anti-cancer therapies other than those administered in this study\n* Baseline QTc \\>470 ms or symptomatic bradycardia\n* Administration of strong/potent cytochrome P4503A inhibitors or inducers within 14 days prior to the receiving the first dose of study treatment and during treatment with alectinib or crizotinib\n* Administration of agents with potential QT interval prolonging effects within 14 days prior to receiving the first dose of study drug\n* History of hypersensitivity to any of the additives in the alectinib or crizotinib drug formulation\n* Pregnant or lactating\n* Known human immunodeficiency virus (HIV-positivity or acquired immunodeficiency syndrome (AIDS)-related illness\n* Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the participant in this study\n* Any psychological, familial, sociological, or geographical condition that potentially hampers compliance with the study protocol requirements or follow-up procedures; those conditions should be discussed with the participant before study entry', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Clinical Trials', 'affiliation': 'Hoffmann-La Roche', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Beijing Cancer Hospital', 'city': 'Beijing', 'zip': '100142', 'country': 'China', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'facility': 'Beijing Chest Hospital', 'city': 'Beijing', 'zip': '101149', 'country': 'China', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'facility': 'the First Hospital of Jilin University', 'city': 'Changchun', 'zip': '130021', 'country': 'China', 'geoPoint': {'lat': 43.88, 'lon': 125.32278}}, {'facility': 'Jilin Cancer Hospital', 'city': 'Changchun', 'zip': '132013', 'country': 'China', 'geoPoint': {'lat': 43.88, 'lon': 125.32278}}, {'facility': 'West China Hospital, Sichuan University', 'city': 'Chengdu', 'zip': '610041', 'country': 'China', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'facility': 'Sun Yet-sen University Cancer Center', 'city': 'Guangzhou', 'zip': '510060', 'country': 'China', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'facility': 'Guangdong General Hospital', 'city': 'Guangzhou', 'zip': '510080', 'country': 'China', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'facility': 'The First Affiliated Hospital of Guangzhou Medical University', 'city': 'Guangzhou', 'zip': '510120', 'country': 'China', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'facility': 'The First Affiliated Hospital of College of Medicine, Zhejiang University', 'city': 'Hangzhou', 'zip': '310003', 'country': 'China', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'facility': 'Zhejiang Cancer Hospital', 'city': 'Hangzhou', 'zip': '310022', 'country': 'China', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'facility': 'Harbin Medical University Cancer Hospital', 'city': 'Harbin', 'zip': '150081', 'country': 'China', 'geoPoint': {'lat': 45.75, 'lon': 126.65}}, {'facility': 'Jiangsu Cancer Hospital', 'city': 'Nanjing', 'zip': '210009', 'country': 'China', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'facility': 'Shanghai chest hospital', 'city': 'Shanghai', 'zip': '200030', 'country': 'China', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'facility': 'Fudan University Shanghai Cancer Center', 'city': 'Shanghai', 'zip': '200032', 'country': 'China', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'facility': 'Shanghai Pulmonary Hospital', 'city': 'Shanghai', 'zip': '200433', 'country': 'China', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'facility': 'Kangbuk Samsung Hospital', 'city': 'Seoul', 'zip': '03181', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Asan Medical Center', 'city': 'Seoul', 'zip': '05505', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Samsung Medical Center', 'city': 'Seoul', 'zip': '06351', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Rajavithi Hospital', 'city': 'Bangkok', 'zip': '10400', 'country': 'Thailand', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'facility': 'Ramathibodi Hospital', 'city': 'Bangkok', 'zip': '10400', 'country': 'Thailand', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'facility': 'Songklanagarind Hospital', 'city': 'Songkhla', 'zip': '90110', 'country': 'Thailand', 'geoPoint': {'lat': 7.19882, 'lon': 100.5951}}]}, 'referencesModule': {'references': [{'pmid': '30981696', 'type': 'DERIVED', 'citation': 'Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019 May;7(5):437-446. doi: 10.1016/S2213-2600(19)30053-0. Epub 2019 Apr 10.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': ""For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\\_sharing""}}","{'participantFlowModule': {'recruitmentDetails': 'Asian adult participants with treatment-naive anaplastic lymphoma kinase (ALK)-positive advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) were enrolled at 21 study sites in 3 countries - China, Korea, and Thailand.', 'groups': [{'id': 'FG000', 'title': 'Alectinib', 'description': 'Participants received alectinib capsules orally at a dose of 600 mg twice a day (BID) with food until disease progression, unacceptable toxicity withdrawal of consent, or death.'}, {'id': 'FG001', 'title': 'Crizotinib', 'description': 'Participants received crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity, withdrawal of consent, or death.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '125'}, {'groupId': 'FG001', 'numSubjects': '62'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '125'}, {'groupId': 'FG001', 'numSubjects': '62'}]}], 'dropWithdraws': [{'type': 'Ongoing in Study', 'reasons': [{'groupId': 'FG000', 'numSubjects': '113'}, {'groupId': 'FG001', 'numSubjects': '45'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '4'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '13'}]}]}]}, 'baselineCharacteristicsModule': {'groups': [{'id': 'BG000', 'title': 'Alectinib', 'description': 'Participants received alectinib capsules orally at a dose of 600 mg twice a day (BID) with food until disease progression, unacceptable toxicity withdrawal of consent, or death.'}, {'id': 'BG001', 'title': 'Crizotinib', 'description': 'Participants received crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity, withdrawal of consent, or death.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '125'}, {'groupId': 'BG001', 'value': '62'}, {'groupId': 'BG002', 'value': '187'}]}], 'measures': [{'title': 'Age, Continuous', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'Years', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '50.5', 'spread': '11.3'}, {'groupId': 'BG001', 'value': '51.1', 'spread': '12.6'}, {'groupId': 'BG002', 'value': '50.7', 'spread': '11.7'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '61'}, {'groupId': 'BG001', 'value': '28'}, {'groupId': 'BG002', 'value': '89'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '64'}, {'groupId': 'BG001', 'value': '34'}, {'groupId': 'BG002', 'value': '98'}]}]}]}, {'title': 'Ethnicity (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '124'}, {'groupId': 'BG001', 'value': '60'}, {'groupId': 'BG002', 'value': '184'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '1'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '3'}]}]}]}, {'title': 'Race (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Asian', 'measurements': [{'groupId': 'BG000', 'value': '125'}, {'groupId': 'BG001', 'value': '62'}, {'groupId': 'BG002', 'value': '187'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Black or African American', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'White', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'More than one race', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1', 'description': 'PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by the investigators, or to death from any cause, whichever occurred first.', 'populationDescription': 'The primary analysis population for efficacy was the intent-to-treat (ITT) population, defined as all randomized participants.', 'reportingStatus': 'POSTED', 'paramType': 'MEDIAN', 'dispersionType': '95% Confidence Interval', 'unitOfMeasure': 'Months', 'timeFrame': 'From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months)', 'groups': [{'id': 'OG000', 'title': 'Alectinib', 'description': 'Participants received alectinib capsules orally at a dose of 600 mg twice a day (BID) with food until disease progression, unacceptable toxicity withdrawal of consent, or death.'}, {'id': 'OG001', 'title': 'Crizotinib', 'description': 'Participants received crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity, withdrawal of consent, or death.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '125'}, {'groupId': 'OG001', 'value': '62'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': 'NA', 'lowerLimit': '20.3', 'upperLimit': 'NA', 'comment': 'Median and upper bound of 95% CI could not be estimated as PFS had not been reached at the time of data cutoff for the primary end point.'}, {'groupId': 'OG001', 'value': '11.1', 'lowerLimit': '9.1', 'upperLimit': '13.0'}]}]}]}, {'type': 'SECONDARY', 'title': 'PFS as Determined by Independent Review Committee (IRC) Using RECIST v1.1', 'description': 'PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by an independent review committee, or to death from any cause, whichever occurred first.', 'reportingStatus': 'NOT_POSTED', 'timeFrame': 'Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months)', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Using RECIST v1.1', 'reportingStatus': 'NOT_POSTED', 'timeFrame': 'Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months)', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Time to Progression of Disease in the CNS as Determined by IRC Using RECIST v1.1', 'reportingStatus': 'NOT_POSTED', 'timeFrame': 'Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months)', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Time to Progression of Disease in the CNS as Determined by IRC Using Response Assessment in Neuro-Oncology (RANO)', 'reportingStatus': 'NOT_POSTED', 'timeFrame': 'Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months)', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Duration of Response (DOR) Assessed by Investigator Using RECIST v1.1', 'reportingStatus': 'NOT_POSTED', 'timeFrame': 'Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months)', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Overall Survival Time', 'reportingStatus': 'NOT_POSTED', 'timeFrame': 'Baseline, until death (up to overall period of approximately 40 months)', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Non-serious Adverse Events and Serious Adverse Events', 'description': 'An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.', 'populationDescription': 'The safety population was defined as all participants who received at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'Percentage of Participants', 'timeFrame': 'Up to overall period of approximately 40 months', 'groups': [{'id': 'OG000', 'title': 'Alectinib', 'description': 'Participants received alectinib capsules orally at a dose of 600 mg twice a day (BID) with food until disease progression, unacceptable toxicity withdrawal of consent, or death.'}, {'id': 'OG001', 'title': 'Crizotinib', 'description': 'Participants received crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity, withdrawal of consent, or death.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '125'}, {'groupId': 'OG001', 'value': '62'}]}], 'classes': [{'title': 'Serious Adverse Events', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '15.2'}, {'groupId': 'OG001', 'value': '25.8'}]}]}, {'title': 'Non-Serious Adverse Events', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '99.2'}, {'groupId': 'OG001', 'value': '100.0'}]}]}]}, {'type': 'SECONDARY', 'title': 'Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Core (QLQ-C30) Score', 'reportingStatus': 'NOT_POSTED', 'timeFrame': 'Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months)', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Lung Cancer Module (QLQ-LC13) Score', 'reportingStatus': 'NOT_POSTED', 'timeFrame': 'Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months)', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Area Under the Plasma Concentration-time Curve (AUC) of Alectinib and Its Metabolite', 'description': 'AUC was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time.', 'populationDescription': 'The PK evaluable population for this outcome measure was a subset of frequent-sampling Chinese participants who received any dose of alectinib, and who had at least one quantifiable post-baseline PK sample available. This outcome measure was specific to the alectinib arm, and no data was collected from participants in the crizotinib arm.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'Hours*nanogram/milliliter (hr*ng/mL)', 'timeFrame': 'Baseline and Week 4 predose (within 2 hours before administration of study drug)', 'groups': [{'id': 'OG000', 'title': 'Alectinib', 'description': 'Participants received alectinib capsules orally at a dose of 600 mg twice a day (BID) with food until disease progression, unacceptable toxicity withdrawal of consent, or death.'}, {'id': 'OG001', 'title': 'Crizotinib', 'description': 'Participants received crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity, withdrawal of consent, or death.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '20'}, {'groupId': 'OG001', 'value': '0'}]}], 'classes': [{'title': 'Alectinib Baseline', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1590', 'spread': '852'}]}]}, {'title': 'M4 Baseline', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '471', 'spread': '243'}]}]}, {'title': 'Alectinib Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '7760', 'spread': '3270'}]}]}, {'title': 'M4 Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2890', 'spread': '1130'}]}]}]}, {'type': 'SECONDARY', 'title': 'Maximum Plasma Concentration Observed (Cmax) of Alectinib and Its Metabolite', 'description': 'Cmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time.', 'populationDescription': 'The PK evaluable population for this outcome measure was a subset of frequent-sampling Chinese participants who received any dose of alectinib, and who had at least one quantifiable post-baseline PK sample available. This outcome measure was specific to the alectinib arm, and no data was collected from participants in the crizotinib arm.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'Nanograms/milliliter (ng/mL)', 'timeFrame': 'Baseline and Week 4 predose (within 2 hours before administration of study drug)', 'groups': [{'id': 'OG000', 'title': 'Alectinib', 'description': 'Participants received alectinib capsules orally at a dose of 600 mg twice a day (BID) with food until disease progression, unacceptable toxicity withdrawal of consent, or death.'}, {'id': 'OG001', 'title': 'Crizotinib', 'description': 'Participants received crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity, withdrawal of consent, or death.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '20'}, {'groupId': 'OG001', 'value': '0'}]}], 'classes': [{'title': 'Alectinib Baseline', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '255', 'spread': '130'}]}]}, {'title': 'M4 Baseline', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '71.4', 'spread': '33.5'}]}]}, {'title': 'Alectinib Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '861', 'spread': '332'}]}]}, {'title': 'M4 Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '306', 'spread': '111'}]}]}]}, {'type': 'SECONDARY', 'title': 'Time to Cmax (Tmax) of Alectinib and Its Metabolite', 'description': 'Tmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time.', 'populationDescription': 'The PK evaluable population for this outcome measure was a subset of frequent-sampling Chinese participants who received any dose of alectinib, and who had at least one quantifiable post-baseline PK sample available. This outcome measure was specific to the alectinib arm, and no data was collected from participants in the crizotinib arm.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'Hour (hr)', 'timeFrame': 'Baseline and Week 4 predose (within 2 hours before administration of study drug)', 'groups': [{'id': 'OG000', 'title': 'Alectinib', 'description': 'Participants received alectinib capsules orally at a dose of 600 mg twice a day (BID) with food until disease progression, unacceptable toxicity withdrawal of consent, or death.'}, {'id': 'OG001', 'title': 'Crizotinib', 'description': 'Participants received crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity, withdrawal of consent, or death.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '20'}, {'groupId': 'OG001', 'value': '0'}]}], 'classes': [{'title': 'Alectinib Baseline', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '5.61', 'spread': '3.02'}]}]}, {'title': 'M4 Baseline', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '8.19', 'spread': '2.30'}]}]}, {'title': 'Alectinib Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4.30', 'spread': '2.45'}]}]}, {'title': 'M4 Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4.11', 'spread': '3.06'}]}]}]}]}, 'adverseEventsModule': {'frequencyThreshold': '5', 'timeFrame': 'Up to approximately 40 months', 'description': 'The safety population was defined as all participants who received at least one dose of study drug. All participants in the ITT population received at least one dose of study drug and were included in the safety population.', 'eventGroups': [{'id': 'EG000', 'title': 'Alectinib', 'description': 'Participants received alectinib capsules orally at a dose of 600 mg twice a day (BID) with food until disease progression, unacceptable toxicity withdrawal of consent, or death.', 'deathsNumAffected': 8, 'deathsNumAtRisk': 125, 'seriousNumAffected': 19, 'seriousNumAtRisk': 125, 'otherNumAffected': 124, 'otherNumAtRisk': 125}, {'id': 'EG001', 'title': 'Crizotinib', 'description': 'Participants received crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity, withdrawal of consent, or death.', 'deathsNumAffected': 13, 'deathsNumAtRisk': 62, 'seriousNumAffected': 16, 'seriousNumAtRisk': 62, 'otherNumAffected': 62, 'otherNumAtRisk': 62}], 'seriousEvents': [{'term': 'Lung infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 62}]}, {'term': 'Pneumonia', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 62}]}, {'term': 'Appendicitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 62}]}, {'term': 'Bronchitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Escherichia sepsis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 62}]}, {'term': 'Upper respiratory tract infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Wound infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Blood uric acid increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 3, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 62}]}, {'term': 'Blood creatine phosphokinase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 62}]}, {'term': 'Alanine aminotransferase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 62}]}, {'term': 'Blood bilirubin increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Interstitial lung disease', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 3, 'numAtRisk': 62}]}, {'term': 'Dyspnoea', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Pleural effusion', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Pneumothorax', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Respiratory failure', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Brain ooedema', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Cerebral infarction', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Intracranial pressure increased', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 62}]}, {'term': 'Paraplegia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Spinal cord compression', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 62}]}, {'term': 'Bradycardia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 62}]}, {'term': 'Pericardial effusion', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Death', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Fatigue', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 62}]}, {'term': 'Pyrexia', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Hepatic function abnormal', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 62}]}, {'term': 'Drug-induced liver injury', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 62}]}, {'term': 'Post procedural ooedema', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Rib fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Wound dehiscence', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Anaemia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Hypokalaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Suicide attempt', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Acute kidney injury', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Dysfunctional uterine bleeding', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 62}]}, {'term': 'Abortion induced', 'organSystem': 'Surgical and medical procedures', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Venous thrombosis', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 62}]}], 'otherEvents': [{'term': 'Aspartate aminotransferase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 65, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 31, 'numAtRisk': 62}]}, {'term': 'Alanine aminotransferase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 52, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 34, 'numAtRisk': 62}]}, {'term': 'Blood creatine phosphokinase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 55, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 18, 'numAtRisk': 62}]}, {'term': 'Blood bilirubin increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 61, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 62}]}, {'term': 'Blood alkaline phosphatase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 33, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 8, 'numAtRisk': 62}]}, {'term': 'Blood creatinine increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 25, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 15, 'numAtRisk': 62}]}, {'term': 'Bilirubin conjugated increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 33, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 62}]}, {'term': 'Weight increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 23, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 62}]}, {'term': 'Gamma-glutamyltransferase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 5, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 17, 'numAtRisk': 62}]}, {'term': 'Haemoglobin decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 18, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 3, 'numAtRisk': 62}]}, {'term': 'White blood cell count decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 6, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 15, 'numAtRisk': 62}]}, {'term': 'Blood lactate dehydrogenase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 11, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 7, 'numAtRisk': 62}]}, {'term': 'Neutrophil count decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 4, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 12, 'numAtRisk': 62}]}, {'term': 'Blood bilirubin unconjugated increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 14, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 62}]}, {'term': 'Blood thyroid stimulating hormone increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 12, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 62}]}, {'term': 'Electrocardiogram QT prolonged', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 4, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 7, 'numAtRisk': 62}]}, {'term': 'Blood albumin decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 4, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 5, 'numAtRisk': 62}]}, {'term': 'Blood creatine phosphokinase MB increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 4, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 5, 'numAtRisk': 62}]}, {'term': 'Weight decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 5, 'numAtRisk': 62}]}, {'term': 'Protein total decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 4, 'numAtRisk': 62}]}, {'term': 'Constipation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 45, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 31, 'numAtRisk': 62}]}, {'term': 'Diarrhoea', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 16, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 31, 'numAtRisk': 62}]}, {'term': 'Nausea', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 8, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 21, 'numAtRisk': 62}]}, {'term': 'Vomiting', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 7, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 22, 'numAtRisk': 62}]}, {'term': 'Fatigue', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 11, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 9, 'numAtRisk': 62}]}, {'term': 'Pyrexia', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 11, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 9, 'numAtRisk': 62}]}, {'term': 'Chest pain', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 10, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 8, 'numAtRisk': 62}]}, {'term': 'Oedema peripheral', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 8, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 10, 'numAtRisk': 62}]}, {'term': 'Chest discomfort', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 10, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 3, 'numAtRisk': 62}]}, {'term': 'Asthenia', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 6, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 5, 'numAtRisk': 62}]}, {'term': 'Oedema', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 9, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 62}]}, {'term': 'Sinus bradycardia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 37, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 11, 'numAtRisk': 62}]}, {'term': 'Bradycardia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 12, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 5, 'numAtRisk': 62}]}, {'term': 'Upper respiratory tract infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 23, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 6, 'numAtRisk': 62}]}, {'term': 'Nasopharyngitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 15, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 3, 'numAtRisk': 62}]}, {'term': 'Urinary tract infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 8, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 62}]}, {'term': 'Lung infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 2, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 4, 'numAtRisk': 62}]}, {'term': 'Anaemia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 38, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 14, 'numAtRisk': 62}]}, {'term': 'Neutropenia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 5, 'numAtRisk': 62}]}, {'term': 'Cough', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 27, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 11, 'numAtRisk': 62}]}, {'term': 'Dyspnoea', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 12, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 5, 'numAtRisk': 62}]}, {'term': 'Productive cough', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 7, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 3, 'numAtRisk': 62}]}, {'term': 'Decreased appetite', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 6, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 22, 'numAtRisk': 62}]}, {'term': 'Hypoalbuminaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 6, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 8, 'numAtRisk': 62}]}, {'term': 'Hypokalaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 10, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 4, 'numAtRisk': 62}]}, {'term': 'Hyponatraemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 4, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 9, 'numAtRisk': 62}]}, {'term': 'Hypoproteinaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 4, 'numAtRisk': 62}]}, {'term': 'Back pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 11, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 10, 'numAtRisk': 62}]}, {'term': 'Musculoskeletal pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 12, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 3, 'numAtRisk': 62}]}, {'term': 'Pain in extremity', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 9, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 6, 'numAtRisk': 62}]}, {'term': 'Myalgia', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 11, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 2, 'numAtRisk': 62}]}, {'term': 'Rash', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 21, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 3, 'numAtRisk': 62}]}, {'term': 'Pruritis', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 12, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 5, 'numAtRisk': 62}]}, {'term': 'Dizziness', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 7, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 13, 'numAtRisk': 62}]}, {'term': 'Headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 7, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 10, 'numAtRisk': 62}]}, {'term': 'Dysgeusia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 10, 'numAtRisk': 62}]}, {'term': 'Liver injury', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 14, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 4, 'numAtRisk': 62}]}, {'term': 'Hepatic function abnormal', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 9, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 4, 'numAtRisk': 62}]}, {'term': 'Insomnia', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 7, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 6, 'numAtRisk': 62}]}, {'term': 'Vision blurred', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 2, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 9, 'numAtRisk': 62}]}, {'term': 'Haematuria', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA version 21.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 8, 'numAtRisk': 125}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 62}]}]}, 'moreInfoModule': {'certainAgreement': {'piSponsorEmployee': False, 'restrictionType': 'OTHER', 'restrictiveAgreement': True, 'otherDetails': ""The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.""}, 'pointOfContact': {'title': 'Medical Communications', 'organization': 'Hoffmann-La Roche', 'email': 'genentech@druginfo.com', 'phone': '800-821-8590'}}}","{'largeDocumentModule': {'largeDocs': [{'typeAbbrev': 'Prot', 'hasProtocol': True, 'hasSap': False, 'hasIcf': False, 'label': 'Study Protocol', 'date': '2017-03-23', 'uploadDate': '2019-05-29T12:24', 'filename': 'Prot_000.pdf', 'size': 1764466}, {'typeAbbrev': 'SAP', 'hasProtocol': False, 'hasSap': True, 'hasIcf': False, 'label': 'Statistical Analysis Plan', 'date': '2018-08-08', 'uploadDate': '2019-05-29T12:24', 'filename': 'SAP_001.pdf', 'size': 439575}]}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'interventionBrowseModule': {'meshes': [{'id': 'C582670', 'term': 'alectinib'}, {'id': 'D000077547', 'term': 'Crizotinib'}], 'ancestors': [{'id': 'D010880', 'term': 'Piperidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D000631', 'term': 'Aminopyridines'}, {'id': 'D011725', 'term': 'Pyridines'}]}}",True
"{'identificationModule': {'nctId': 'NCT06286150', 'orgStudyIdInfo': {'id': 'EC-2023-087(QX)-03'}, 'organization': {'fullName': 'The First Affiliated Hospital of Guangzhou Medical University', 'class': 'OTHER'}, 'briefTitle': 'Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery', 'officialTitle': 'Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery: A Prospective, Single Center Study'}, 'statusModule': {'statusVerifiedDate': '2024-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-09-15', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-07-15', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-07-15', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-02-15', 'studyFirstSubmitQcDate': '2024-02-22', 'studyFirstPostDateStruct': {'date': '2024-02-29', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-22', 'lastUpdatePostDateStruct': {'date': '2024-02-29', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Jianxing He', 'investigatorTitle': 'Director', 'investigatorAffiliation': 'The First Affiliated Hospital of Guangzhou Medical University'}, 'leadSponsor': {'name': 'The First Affiliated Hospital of Guangzhou Medical University', 'class': 'OTHER'}}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Robotic surgical systems have become a promising surgical assistance system, with unique advantages such as 3D high-definition visual system, highly flexible wrist-jointed instruments, and automatic fitering of hand tremors. Robotic surgical systems is applied in various fields including urology, general surgery, cardiothoracic surgery, head and neck surgery, and gynecology. Currently, the Da Vinci surgical robot system is the most widely used robot system globally. However, the Da Vinci robot system for single-port laparoscopic surgery has not yet been launched in China. Therefore, the investigators conduct a prespective, single-center study to evaluate the efficacy and safety of single-port surgical robot system in thoracic surgery.'}, 'conditionsModule': {'conditions': ['Lung Cancer'], 'keywords': ['surgical robot system', 'efficacy', 'safety', 'thoracic surgery']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 20, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'single-port robot group', 'type': 'EXPERIMENTAL', 'interventionNames': ['Procedure: Surgical robot system']}], 'interventions': [{'type': 'PROCEDURE', 'name': 'Surgical robot system', 'description': 'SHURUI Single-port surgical robot system', 'armGroupLabels': ['single-port robot group']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Intraoperative conversion rate', 'description': 'The conversion from a single-port laparoscopic surgery system to other surgical Instrument control systems, such as traditional thoracoscopy or open surgery.', 'timeFrame': 'Within 1 day after surgery'}, {'measure': 'Surgical complications rate', 'description': 'The incidence rate of instrument-related or potentially instrument-related surgical complications meeting Clavien-Dindo grade 3 or above criteria from the time of incision', 'timeFrame': '30 days after surgery'}], 'secondaryOutcomes': [{'measure': 'Intraoperating bleeding volume', 'description': 'The amount of intraoperative bleeding from the start to the end of the surgery in the study subjects', 'timeFrame': 'Within 1 day after surgery'}, {'measure': 'Surgical time', 'timeFrame': 'Within 1 day after surgery'}, {'measure': 'Length of hospital admissions', 'description': 'The total number of days of hospitalization from the day of surgery to discharge for the study subjects.\n\nIf a subject is admitted in the afternoon or discharged in the morning, the day of admission or discharge is recorded as 0.5 days.', 'timeFrame': 'Within 30 day after surgery'}, {'measure': 'Postoperative wound pain score', 'description': 'Assessment will be conducted using the Numerical Rating Scale (NRS)', 'timeFrame': '1, 24 and 72 hours after surgery'}, {'measure': 'Surgeon satisfaction', 'description': 'The surgeon satisfaction survey questionnaire consists of two parts: performance-related (12 questions) and surgeon comfort-related ratings (8 questions). The scoring criteria are as follows: Each question is scored on a scale of 1-5, with a maximum score of 5. The total score is out of 100', 'timeFrame': 'Within 4 hours after surgery'}, {'measure': 'Adverse events', 'description': 'Incidence of adverse events (AE), serious adverse events (SAE), and overall surgical complication rate (evaluated using the Clavien-Dindo grading system)', 'timeFrame': 'Within 1 day after surgery'}, {'measure': 'Rate of re-admission to hospital', 'timeFrame': '30 days after discharge'}, {'measure': 'Rate of reoperation', 'timeFrame': '30 days after surgery'}, {'measure': 'Postoperative mortality', 'timeFrame': '30 days after surgery'}]}, 'eligibilityModule': {'eligibilityCriteria': ""Inclusion Criteria:\n\n* Age between 18 and 75 years, regardless of gender.\n* Patients who require endoscopic surgical treatment and have indications for lung segment/lobe resection; for pre-trial subjects, there is no restriction on the type of procedure, and inclusion is based on the investigator's judgment of having indications for thoracic surgery.\n* Preoperative ASA classification of I-III.\n* Voluntary participation in the clinical trial and willingness to provide informed.\n\nconsent, either by the subject or their guardian.\n\n* Willingness to cooperate and complete trial follow-up and related examinations.\n\nExclusion Criteria:\n\n* Patients with a history of thoracic surgery or previous history of other malignant tumors deemed unsuitable for inclusion by the investigator.\n* Patients with severe comorbidities (cardiac, pulmonary, hepatic, cerebral, renal diseases) or physical weakness who cannot tolerate general anesthesia or surgery.\n* Patients with severe bleeding tendencies or coagulation disorders.\n* Patients in the active phase of infectious diseases or with other severe non-communicable infections.\n* Patients positive for Human Immunodeficiency Virus (HIV) antibodies or syphilis seropositive patients.\n* Patients with a suspected or confirmed alcohol, drug, or substance addiction.\n* Patients with a history of epilepsy, mental illness, or cognitive impairment.\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the trial period.\n* Participation in other interventional clinical trials within 3 months prior to signing the informed consent form.\n* Other situations in which the investigator deems inappropriate for participation in this clinical trial."", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Jianxing He, M.D.', 'role': 'CONTACT', 'phone': '+86-20-83337792', 'email': 'hejx@vip.163.com'}], 'locations': [{'facility': 'The First Affiliated Hospital of Guangzhou Medical University', 'status': 'RECRUITING', 'city': 'Guangzhou', 'state': 'Guangdong', 'zip': '510000', 'country': 'China', 'contacts': [{'name': 'Jianxing He, M.D.', 'role': 'CONTACT', 'phone': '+86-20-83337792', 'email': 'hejx@vip.163.com'}], 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}]}}",,,"{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}}",False
"{'identificationModule': {'nctId': 'NCT07143513', 'orgStudyIdInfo': {'id': '20240175'}, 'organization': {'fullName': 'Amgen', 'class': 'INDUSTRY'}, 'briefTitle': 'Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients', 'officialTitle': 'Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients'}, 'statusModule': {'statusVerifiedDate': '2025-09', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-08-11', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-02-28', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-08-20', 'studyFirstSubmitQcDate': '2025-08-20', 'studyFirstPostDateStruct': {'date': '2025-08-27', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-09-10', 'lastUpdatePostDateStruct': {'date': '2025-09-12', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Amgen', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The primary objective of this study is to characterize the safety profile of sotorasib.'}, 'conditionsModule': {'conditions': ['Non-Small Cell Lung Cancer'], 'keywords': ['Non-Small Cell Lung Cancer', 'Sotorasib', 'AMG 510']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 115, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Chinese Participants Treated with Sotorasib', 'description': 'Adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) p.G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and previously treated with at least 1 prior systemic therapy that have received sotorasib treatment in either location of BOAO Pilot Zone and Hong Kong SAR will be included in this cohort.\n\nThe duration of evidence collection is from initiation of sotorasib to the end of study period, up to approximately 4 years from the date of the first available sotorasib use in BOAO Pilot Zone of around August 2021.', 'interventionNames': ['Drug: Sotorasib']}], 'interventions': [{'type': 'DRUG', 'name': 'Sotorasib', 'description': 'Participants will have received sotorasib orally daily until disease progression or unacceptable toxicity.', 'armGroupLabels': ['Chinese Participants Treated with Sotorasib'], 'otherNames': ['AMG 510']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants with Treatment-emergent Adverse Events (TEAEs)', 'timeFrame': 'Up to approximately 4 years'}, {'measure': 'Number of Participants with Adverse Events of Interest, Inclusive of Hepatotoxicity, Interstitial Lung Disease/Pneumonitis, and Renal Toxicity', 'timeFrame': 'Up to approximately 4 years'}, {'measure': 'Number of Participants with Treatment-related Adverse Events (AEs)', 'timeFrame': 'Up to approximately 4 years'}, {'measure': 'Number of Participants with Treatment-related AEs of Grade 3 or Worse', 'timeFrame': 'Up to approximately 4 years'}, {'measure': 'Number of Participants with Serious Treatment-related AEs', 'timeFrame': 'Up to approximately 4 years'}, {'measure': 'Number of Participants with Treatment-related AEs Leading to Treatment Discontinuation', 'timeFrame': 'Up to approximately 4 years'}, {'measure': 'Number of Participants with Treatment-related AEs Leading to Dose Reduction', 'timeFrame': 'Up to approximately 4 years'}, {'measure': 'Number of Participants with Treatment-related AEs Leading to Death', 'timeFrame': 'Up to approximately 4 years'}], 'secondaryOutcomes': [{'measure': 'Overall Survival (OS) from Initial Date of Sotorasib Use to Date of Death', 'timeFrame': 'Up to approximately 4 years'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* Adult (≥ 18 years) as of the index date.\n* KRAS p.G12C-mutated locally advanced or metastatic NSCLC.\n* Received at least 1 dose of sotorasib.\n* Receipt of at least 1 prior systemic therapy before use of sotorasib.\n* Obtained ICF, if required.\n\nExclusion Criteria:\n\n* Documentation of being a non-Chinese ethnicity.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'The target population is adult participants with KRAS p.G12C-mutated locally advanced or metastatic NSCLC and previously treated with at least 1 prior systemic therapy that have received sotorasib treatment in either location of BOAO Pilot Zone and Hong Kong SAR.', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Amgen Call Center', 'role': 'CONTACT', 'phone': '866-572-6436', 'email': 'medinfo@amgen.com'}], 'overallOfficials': [{'name': 'MD', 'affiliation': 'Amgen', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Boao Evergrande International Hospital', 'status': 'RECRUITING', 'city': 'Qionghai', 'state': 'Hainan', 'zip': '571400', 'country': 'China', 'geoPoint': {'lat': 19.2425, 'lon': 110.46417}}, {'facility': 'Boao Super Hospital', 'status': 'RECRUITING', 'city': 'Qionghai', 'state': 'Hainan', 'zip': '571499', 'country': 'China', 'geoPoint': {'lat': 19.2425, 'lon': 110.46417}}, {'facility': 'Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine Hainan Boao Research Hospital', 'status': 'RECRUITING', 'city': 'Qionghai', 'state': 'Hainan', 'zip': '57400', 'country': 'China', 'geoPoint': {'lat': 19.2425, 'lon': 110.46417}}]}, 'referencesModule': {'seeAlsoLinks': [{'label': 'AmgenTrials clinical trials website', 'url': 'http://www.amgentrials.com'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR'], 'timeFrame': 'Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.', 'accessCriteria': 'Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.', 'url': 'https://www.amgen.com/datasharing'}}",,,"{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000706028', 'term': 'sotorasib'}]}}",False
"{'identificationModule': {'nctId': 'NCT06695845', 'orgStudyIdInfo': {'id': 'JZP598-206'}, 'secondaryIdInfos': [{'id': '2024-516551-41-00', 'type': 'CTIS'}], 'organization': {'fullName': 'Jazz Pharmaceuticals', 'class': 'INDUSTRY'}, 'briefTitle': 'A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors', 'officialTitle': 'A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)'}, 'statusModule': {'statusVerifiedDate': '2025-12', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-01-14', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-12-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-11-16', 'studyFirstSubmitQcDate': '2024-11-16', 'studyFirstPostDateStruct': {'date': '2024-11-19', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-12-17', 'lastUpdatePostDateStruct': {'date': '2025-12-18', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Jazz Pharmaceuticals', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Jazz Pharmaceuticals Ireland Limited', 'class': 'INDUSTRY'}]}, 'oversightModule': {'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.'}, 'conditionsModule': {'conditions': ['Breast Cancer', 'Gastric Cancer', 'Esophageal Cancer', 'Gastroesophageal Cancer', 'Colorectal Cancer', 'Endometrial Cancer', 'Non-small Cell Lung Cancer', 'Ovarian Cancer', 'Urothelial Carcinoma', 'Salivary Gland Cancer', 'Pancreatic Cancer', 'HER-2 Protein Overexpression'], 'keywords': ['JZP598', 'ZW25', 'HER2 IHC 3+ Overexpression Solid Tumors']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 200, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Zanidatamab treatment arm', 'type': 'EXPERIMENTAL', 'description': 'Eligible participants receiving zanidatamab treatment', 'interventionNames': ['Drug: Zanidatamab']}], 'interventions': [{'type': 'DRUG', 'name': 'Zanidatamab', 'description': 'Administered by intravenous (IV) infusion', 'armGroupLabels': ['Zanidatamab treatment arm'], 'otherNames': ['ZW25', 'JZP598', 'ZIIHERA®']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR', 'description': 'The Independent Central Review (ICR) assessed cORR is defined as the proportion of participants who had a best overall response of Complete Response (CR), or Partial Response (PR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)', 'timeFrame': 'Up to 2.5 years'}], 'secondaryOutcomes': [{'measure': 'Duration of Response (DOR) Per RECIST Version 1.1, as assessed by ICR', 'description': 'ICR assessed DOR is defined as the time in months from the first objective response (CR or PR) that is subsequently confirmed to documented progressive disease (PD) per RECIST v1.1 or death from any cause.', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'cORR by RECIST Version 1.1, as assessed by Investigator', 'description': 'Investigator assessed cORR is defined as the proportion of participants who had a best overall response of Complete Response (CR), or Partial Response (PR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Duration of Response (DOR) Per RECIST Version 1.1, as assessed by Investigator', 'description': 'Investigator assessed DOR is defined as the time in months from the first objective response (CR or PR) that is subsequently confirmed to documented progressive disease (PD) per RECIST v1.1 or death from any cause.', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Time to Response (TTR), as assessed by ICR', 'description': 'ICR assessed TTR is defined as the time from the first dosing date to the first objective response (CR or PR) per RECIST v1.1.', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Time to Response (TTR), as assessed by Investigator', 'description': 'Investigator assessed TTR is defined as the time from the first dosing date to the first objective response (CR or PR) per RECIST v1.1.', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Disease control rate (DCR), as assessed by ICR', 'description': 'ICR assessed DCR is defined as the proportion of participants whose best overall response (BOR) is confirmed CR, or PR, or stable disease using the RECIST version 1.1 criteria', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Disease control rate (DCR), as assessed by Investigator', 'description': 'Investigator assessed DCR is defined as the proportion of participants whose best overall response (BOR) is confirmed CR, or PR, or stable disease using the RECIST version 1.1 criteria', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Progression Free Survival (PFS), as assessed by ICR', 'description': 'PFS is defined as the time in months from the first dosing date to the date of first documented disease progression (as assessed by ICR according to RECIST v1.1) or death from any cause, whichever occurs first.', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Progression Free Survival (PFS), as assessed by Investigator', 'description': 'PFS is defined as the time in months from the first dosing date to the date of first documented disease progression (as assessed by Investigator according to RECIST v1.1) or death from any cause, whichever occurs first.', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time in months from randomization to the date of death due to any cause.', 'timeFrame': 'Up to 3.5 years'}, {'measure': 'Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) As Graded by NCI CTCAE Version 5.0', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Number of Participants With Dose Reductions', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Number of Participants Discontinuing Study Treatment Due to TEAEs', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Serum Concentrations of Zanidatamab', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Number of Participants Positive for Anti-drug Antibodies to Zanidatamab', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Number of participants reporting Symptomatic Adverse Events based on Patient-reported Outcome-Common Terminology Criteria for AEs (PRO-CTCAE)', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Number of participants reporting Symptomatic Adverse Events based on European Organisation for Research and Treatment of Cancer (EORTC) Item Library', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Percentage of all treated participants reporting overall side-effect bother on the Functional Assessment of Chronic Illness Therapy General Physical Item 5 (FACIT-GP5)', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Percentage of time when participants on treatment reported a high side-effect bother on the Functional Assessment of Chronic Illness Therapy General Physical Item 5 (FACIT-GP5)', 'timeFrame': 'Up to 2.5 years'}]}, 'eligibilityModule': {'eligibilityCriteria': ""Inclusion Criteria:\n\n1. Is at least 18 years of age inclusive at the time of signing the informed consent\n2. Participants with locally advanced, unresectable, or metastatic solid tumors (except Biliary Tract Cancer (BTC), defined as gallbladder cancer or cholangiocarcinoma) who have progressed following at least 1 prior systemic treatment for metastatic or advanced disease and have no available treatment options that have confirmed benefit. Prior treatment with HER2-targeted therapy is not permitted (Cohort 1 only). For participants with breast cancer (Cohort 2) or GEA (Cohort 3), prior HER2-targeted therapy is permitted and prior therapy with trastuzumab deruxtecan (T-DXd) is required.\n3. HER2 overexpression (IHC 3+) must be determined by a sponsor designated central laboratory.\n4. All participants must have adequate tumor sample for submission to allow central HER2 testing.\n5. Presence of at least 1 measurable lesion as assessed by Independent Central Review (ICR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\n6. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n7. Has a life expectancy of at least 3 months, in the opinion of the investigator.\n8. Participants with history of treated and stable CNS metastases are eligible, provided the following criteria are met:\n\n   1. Participants also have measurable metastatic disease with HER2 overexpression (IHC 3+) outside the CNS.\n   2. Participants with treated CNS metastases that are no longer symptomatic may be included in the study if they recovered to \\< Grade 1 (CTCAE Version 5.0 or higher) or baseline from the acute toxic effect associated with the treatment \\> 7 days prior to Cycle 1 Day 1.\n   3. Prior stereotactic radiosurgery or stereotactic radiotherapy should be completed at least 7 days (≥ 7 days) before the first dose of study intervention.\n9. Adequate organ functions.\n10. Females of childbearing potential must have a negative pregnancy test result.\n11. Females of childbearing potential and males with a partner of childbearing potential must be willing to use 2 methods of birth control.\n\nExclusion Criteria:\n\n1. Has known or suspected leptomeningeal disease and/or untreated brain metastasis.\n2. Has uncontrolled or significant cardiovascular disease\n3. Has ongoing toxicity related to prior cancer therapy\n4. Has uncontrolled infection or requiring IV antibiotics, antivirals, or antifungals.\n5. Has known Human Immunodeficiency Virus (HIV) infection.\n6. Has active hepatitis B or C infection.\n7. Has an active SARS-CoV-2 infection.\n8. Has a history of life-threatening hypersensitivity to monoclonal antibody (mAbs) or to recombinant proteins or excipients in the drug formulation of zanidatamab.\n9. Has any serious underlying medical or psychiatric condition that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site.\n10. Has any issue or condition that, in the opinion of the investigator, would contraindicate the participant's participation in the study or confound the results of the study.\n11. Prior treatment with HER2-targeted therapy (Cohort 1 only).\n12. Has a history of trauma or major surgery\n13. Was treated with systemic antineoplastic therapy, including hormonal therapies for breast cancer, or any investigational therapy within 4 weeks or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.\n14. Received zanidatamab at any time prior to the current study.\n15. Colorectal Cancer (CRC) participants with known KRAS/NRAS and BRAF mutations.\n16. Non-Small Cell Lung Cancer (NSCLC) participants with known ALK, EGFR mutations and ROS1 fusion.\n17. Female participants who are breastfeeding or pregnant, and female and male participants planning a pregnancy.\n18. Prior or concurrent invasive malignancy other than the disease under study, whose natural history or treatment has, in the opinion of the investigator or medical monitor, the potential to interfere with the safety or efficacy assessment of the investigational regimen."", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Clinical Trial Disclosure & Transparency', 'role': 'CONTACT', 'phone': '215-832-3750', 'email': 'ClinicalTrialDisclosure@JazzPharma.com'}], 'locations': [{'facility': 'Arizona Oncology Associates, PC - NAHOA', 'status': 'RECRUITING', 'city': 'Prescott', 'state': 'Arizona', 'zip': '86301', 'country': 'United States', 'geoPoint': {'lat': 34.54002, 'lon': -112.4685}}, {'facility': 'Rocky Mountain Cancer Center', 'status': 'RECRUITING', 'city': 'Littleton', 'state': 'Colorado', 'zip': '80120', 'country': 'United States', 'geoPoint': {'lat': 39.61332, 'lon': -105.01665}}, {'facility': 'Florida Cancer Specialists - South', 'status': 'RECRUITING', 'city': 'Fort Myers', 'state': 'Florida', 'zip': '33901', 'country': 'United States', 'geoPoint': {'lat': 26.62168, 'lon': -81.84059}}, {'facility': 'Florida Cancer Specialists - Lake Nona', 'status': 'RECRUITING', 'city': 'Orlando', 'state': 'Florida', 'zip': '32827', 'country': 'United States', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'facility': 'Florida Cancer Specialists - North', 'status': 'RECRUITING', 'city': 'St. Petersburg', 'state': 'Florida', 'zip': '33705', 'country': 'United States', 'geoPoint': {'lat': 27.77086, 'lon': -82.67927}}, {'facility': 'Florida Cancer Specialists - East', 'status': 'RECRUITING', 'city': 'West Palm Beach', 'state': 'Florida', 'zip': '33401', 'country': 'United States', 'geoPoint': {'lat': 26.71534, 'lon': -80.05337}}, {'facility': 'Affiliated Oncologists', 'status': 'RECRUITING', 'city': 'Chicago Ridge', 'state': 'Illinois', 'zip': '60415', 'country': 'United States', 'geoPoint': {'lat': 41.70142, 'lon': -87.77922}}, {'facility': 'Barbara Ann Karmanos Cancer Institute', 'status': 'RECRUITING', 'city': 'Detroit', 'state': 'Michigan', 'zip': '48201', 'country': 'United States', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'facility': 'Alliance Cancer Specialists', 'status': 'RECRUITING', 'city': 'Horsham', 'state': 'Pennsylvania', 'zip': '19044', 'country': 'United States', 'geoPoint': {'lat': 40.17844, 'lon': -75.12851}}, {'facility': 'Tennessee Cancer Specialists', 'status': 'RECRUITING', 'city': 'Knoxville', 'state': 'Tennessee', 'zip': '37909', 'country': 'United States', 'geoPoint': {'lat': 35.96064, 'lon': -83.92074}}, {'facility': 'SCRI Oncology Partners', 'status': 'RECRUITING', 'city': 'Nashville', 'state': 'Tennessee', 'zip': '37203', 'country': 'United States', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'facility': 'Texas Oncology - West Texas', 'status': 'RECRUITING', 'city': 'Amarillo', 'state': 'Texas', 'zip': '79124', 'country': 'United States', 'geoPoint': {'lat': 35.222, 'lon': -101.8313}}, {'facility': 'Texas Oncology - DFW', 'status': 'RECRUITING', 'city': 'Dallas', 'state': 'Texas', 'zip': '75246', 'country': 'United States', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'facility': 'MD Anderson Cancer Center', 'status': 'RECRUITING', 'city': 'Houston', 'state': 'Texas', 'zip': '77030', 'country': 'United States', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'facility': 'Texas Oncology - San Antonio', 'status': 'RECRUITING', 'city': 'San Antonio', 'state': 'Texas', 'zip': '78217', 'country': 'United States', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'facility': 'Blue Ridge Cancer Care', 'status': 'RECRUITING', 'city': 'Roanoke', 'state': 'Virginia', 'zip': '24014', 'country': 'United States', 'geoPoint': {'lat': 37.27097, 'lon': -79.94143}}, {'facility': 'Samsung Medical Center', 'status': 'RECRUITING', 'city': 'Gangnam-gu', 'state': 'Seoul', 'zip': '06351', 'country': 'South Korea'}, {'facility': 'Seoul National University Hospital', 'status': 'RECRUITING', 'city': 'Jongno-gu', 'state': 'Seoul', 'zip': '03080', 'country': 'South Korea'}, {'facility': 'Severance Hospital', 'status': 'RECRUITING', 'city': 'Seodaemun-gu', 'state': 'Seoul', 'zip': '03722', 'country': 'South Korea'}, {'facility': 'Asan Medical Center', 'status': 'RECRUITING', 'city': 'Seoul', 'zip': '05505', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Seoul National University Bundang Hospital', 'status': 'RECRUITING', 'city': 'Seoul', 'zip': '13620', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': ""In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com."", 'url': 'https://www.jazzpharma.com/science/clinical-trial-data-sharing'}}",,,"{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}, {'id': 'D013274', 'term': 'Stomach Neoplasms'}, {'id': 'D004938', 'term': 'Esophageal Neoplasms'}, {'id': 'D015179', 'term': 'Colorectal Neoplasms'}, {'id': 'D016889', 'term': 'Endometrial Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}, {'id': 'D010051', 'term': 'Ovarian Neoplasms'}, {'id': 'D002295', 'term': 'Carcinoma, Transitional Cell'}, {'id': 'D012468', 'term': 'Salivary Gland Neoplasms'}, {'id': 'D010190', 'term': 'Pancreatic Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D013272', 'term': 'Stomach Diseases'}, {'id': 'D006258', 'term': 'Head and Neck Neoplasms'}, {'id': 'D004935', 'term': 'Esophageal Diseases'}, {'id': 'D007414', 'term': 'Intestinal Neoplasms'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D012002', 'term': 'Rectal Diseases'}, {'id': 'D014594', 'term': 'Uterine Neoplasms'}, {'id': 'D005833', 'term': 'Genital Neoplasms, Female'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D014591', 'term': 'Uterine Diseases'}, {'id': 'D005831', 'term': 'Genital Diseases, Female'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D004701', 'term': 'Endocrine Gland Neoplasms'}, {'id': 'D010049', 'term': 'Ovarian Diseases'}, {'id': 'D000291', 'term': 'Adnexal Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D006058', 'term': 'Gonadal Disorders'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009062', 'term': 'Mouth Neoplasms'}, {'id': 'D009059', 'term': 'Mouth Diseases'}, {'id': 'D009057', 'term': 'Stomatognathic Diseases'}, {'id': 'D012466', 'term': 'Salivary Gland Diseases'}, {'id': 'D010182', 'term': 'Pancreatic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000726995', 'term': 'zanidatamab'}]}}",False
"{'identificationModule': {'nctId': 'NCT06426628', 'orgStudyIdInfo': {'id': 'DHF009-050P'}, 'organization': {'fullName': 'Veracyte, Inc.', 'class': 'INDUSTRY'}, 'briefTitle': 'Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier', 'officialTitle': 'Clinical Utility of Management of Patients With CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab Classifier', 'acronym': 'NIGHTINGALE'}, 'statusModule': {'statusVerifiedDate': '2024-11', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-07-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-03-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-05-10', 'studyFirstSubmitQcDate': '2024-05-17', 'studyFirstPostDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-11-12', 'lastUpdatePostDateStruct': {'date': '2024-11-13', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Veracyte, Inc.', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The goal of this observational study is to learn how a physician uses the results of the Percepta® Nasal Swab test to manage people with a newly identified pulmonary nodule.\n\nThe main questions it aims to answer are:\n\n* Does the use of the Percepta Nasal swab test reduce the number of invasive procedures in people with a low-risk result and whose nodule is benign?\n* Does the use of the Percepta Nasal swab test decrease the time to treatment in people with a high-risk result and whose nodule is cancer?\n\nParticipants will be randomly assigned to either a group where the test result is provided to the physician (test arm) or to a group where the test result is not provided (control arm). Researchers will compare management of participants in the two groups.', 'detailedDescription': ""This is a prospective, multicenter, randomized study to evaluate the clinical utility of the Percepta® Nasal Swab classifier in managing patients with pulmonary nodules identified incidentally or by lung cancer screening. Patients will be randomized to either the test group, where the test result will be returned to the physician to incorporate into decision-making on how to manage the patient's nodule, or the control group which will represent the standard of care where the result will not be returned to the physician. The study will observe and evaluate how the addition of the Percepta Nasal Swab classifier result impacts current management of newly identified lung nodules.\n\nThe study will enroll approximately 2400 participants meeting eligibility criteria at up to 100 centers in the US. Enrollment is expected to take approximately 24 months and participants will be followed for 24 to 30 months or until a diagnosis of lung cancer.""}, 'conditionsModule': {'conditions': ['Pulmonary Nodule, Solitary', 'Lung Cancer']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA', 'description': 'Nasal swab'}, 'enrollmentInfo': {'count': 2400, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Test Arm', 'description': 'Percepta Nasal Swab test result will be returned to the physician investigator.'}, {'label': 'Control Arm', 'description': 'Percepta Nasal Swab test result will not be returned to the physician investigator.'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of invasive diagnostic procedures', 'description': 'Invasive diagnostic procedures performed in the diagnostic workup of newly identified nodules that are benign.', 'timeFrame': 'From date of randomization until the date the nodule is diagnosed as benign or demonstrates up to 24 months radiographic stability or resolution, assessed up to a total of 30 months.'}], 'secondaryOutcomes': [{'measure': 'Time to treatment', 'description': 'Time to treatment in the diagnostic workup of newly identified nodules that are primary lung cancer', 'timeFrame': 'From date of randomization until the date of first documented treatment for lung cancer, assessed up to a total of 30 months.'}]}, 'eligibilityModule': {'eligibilityCriteria': ""Inclusion Criteria:\n\n* Able to tolerate nasal epithelial specimen collection\n* Signed written Informed Consent obtained\n* Subject clinical history available for review by sponsor and regulatory agencies\n* New nodule identified on imaging \\< 90 days prior to nasal sample collection\n* CT report available for index nodule\n* 29 - 85 years of age\n* Current or former smoker (\\>100 cigarettes in a lifetime)\n* Pulmonary nodule ≤30 mm detected by CT\n\nExclusion Criteria:\n\n* Active cancer (other than non-melanoma skin cancer)\n* Prior primary lung cancer (prior non-lung cancer acceptable)\n* Prior participation in this study (i.e., subjects may not be enrolled more than once)\n* Current active treatment with an investigational device or drug\n* Patient enrolled or planned to be enrolled in another clinical trial that may influence management of the patient's nodule\n* Concurrent or planned use of tools or tests for assigning lung nodule risk of malignancy other than clinically validated risk calculators"", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '29 Years', 'maximumAge': '85 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Current or former smokers (\\>100 cigarettes in a lifetime) who are 29 - 85 years of age with a newly identified pulmonary nodule ≤30 mm detected by CT', 'samplingMethod': 'PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Lori Lofaro, MSHS', 'role': 'CONTACT', 'phone': '6502436389', 'email': 'lori.lofaro@veracyte.com'}], 'overallOfficials': [{'name': 'Phillip G Febbo, MD', 'affiliation': 'Veracyte, Inc.', 'role': 'STUDY_CHAIR'}], 'locations': [{'facility': 'Trinity Health Of New England', 'status': 'RECRUITING', 'city': 'Hartford', 'state': 'Connecticut', 'zip': '06105', 'country': 'United States', 'contacts': [{'name': 'Anil Magge, MD', 'role': 'CONTACT', 'phone': '860-714-4055', 'email': 'anil.magge@trinityhealthofne.org'}, {'name': 'Anil Magge, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 41.76371, 'lon': -72.68509}}, {'facility': 'The Stamford Health/The Stamford Hospital', 'status': 'RECRUITING', 'city': 'Stamford', 'state': 'Connecticut', 'zip': '06904', 'country': 'United States', 'contacts': [{'name': 'Majed Albache, MD, MPH', 'role': 'CONTACT', 'phone': '203-276-4362', 'email': 'Malbache@stamhealth.org'}, {'name': 'Adrienne S Scott, MS, CCRC', 'role': 'CONTACT', 'phone': '203-276-4362', 'email': 'Ascott@stamhealth.org'}, {'name': 'Michael A Bernstein, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 41.05343, 'lon': -73.53873}}, {'facility': 'Bay Pines VA HCS', 'status': 'RECRUITING', 'city': 'Bay Pines', 'state': 'Florida', 'zip': '33744', 'country': 'United States', 'contacts': [{'name': 'Stephen R Clum, MD PhD', 'role': 'CONTACT', 'phone': '727-398-6661', 'phoneExt': '15785', 'email': 'stephen.clum@va.gov'}, {'name': 'Stephen R Clum, MD PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 27.81419, 'lon': -82.77816}}, {'facility': 'North Florida/South Georgia Veterans Health System', 'status': 'RECRUITING', 'city': 'Gainesville', 'state': 'Florida', 'zip': '32608', 'country': 'United States', 'contacts': [{'name': 'Juliana Venetucci', 'role': 'CONTACT', 'phone': '352-548-7707', 'email': 'Juliana.Venetucci@va.gov'}, {'name': 'Peruvemba S Sriram, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 29.65163, 'lon': -82.32483}}, {'facility': 'Bruce W. Carter Miami VA Medical Center', 'status': 'RECRUITING', 'city': 'Miami', 'state': 'Florida', 'zip': '33125', 'country': 'United States', 'contacts': [{'name': 'Jalima Quintero, RN', 'role': 'CONTACT', 'phone': '305-575-7000', 'phoneExt': '14580', 'email': 'Jalima.Quintero@va.gov'}, {'name': 'Gregory E Holt, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'facility': 'Orlando VA Healthcare System', 'status': 'RECRUITING', 'city': 'Orlando', 'state': 'Florida', 'zip': '32827', 'country': 'United States', 'contacts': [{'name': 'Nazia Sultana, MD', 'role': 'CONTACT', 'phone': '407-631-2040', 'email': 'Nazia.sultana@va.gov'}, {'name': 'Nazia Sultana, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'facility': 'Northwestern University', 'status': 'RECRUITING', 'city': 'Chicago', 'state': 'Illinois', 'zip': '60611', 'country': 'United States', 'contacts': [{'name': 'Phillip Cooper', 'role': 'CONTACT', 'phone': '312-503-0406', 'email': 'p-cooper@northwestern.edu'}, {'name': 'Momen M Wahidi, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'facility': 'OSF Saint Francis Medical Center', 'status': 'RECRUITING', 'city': 'Peoria', 'state': 'Illinois', 'zip': '61637', 'country': 'United States', 'contacts': [{'name': 'Kimberly Hartwig, RN, BSN', 'role': 'CONTACT', 'phone': '309-655-4229', 'email': 'Kimberly.Hartwig@osfhealthcare.org'}, {'name': 'Patrick E Whitten, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 40.69365, 'lon': -89.58899}}, {'facility': 'University of Kansas Medical Center', 'status': 'RECRUITING', 'city': 'Kansas City', 'state': 'Kansas', 'zip': '66103', 'country': 'United States', 'contacts': [{'name': 'Vianca Williams, MCR, CCRP', 'role': 'CONTACT', 'phone': '913-588-2814', 'email': 'vwilliams6@kumc.edu'}, {'name': 'Maykol R Postigo, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 39.11417, 'lon': -94.62746}}, {'facility': 'Lexington VA Health Care System', 'status': 'RECRUITING', 'city': 'Lexington', 'state': 'Kentucky', 'zip': '40502', 'country': 'United States', 'contacts': [{'name': 'Rebekah Evans, N, BSN, CCRP', 'role': 'CONTACT', 'phone': '859-233-4511', 'phoneExt': '5223', 'email': 'Rebekah.evans1@va.gov'}, {'name': 'Mouna Abouamara, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 37.98869, 'lon': -84.47772}}, {'facility': 'Robley Rex VA Medical Center', 'status': 'RECRUITING', 'city': 'Louisville', 'state': 'Kentucky', 'zip': '40206', 'country': 'United States', 'contacts': [{'name': 'Fred Hendler, MD, PhD', 'role': 'CONTACT', 'phone': '502-287-5131', 'email': 'Fred.Hendler@va.gov'}, {'name': 'Fred Hendler, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'facility': 'Southeast Louisiana Veterans Health Care System', 'status': 'RECRUITING', 'city': 'New Orleans', 'state': 'Louisiana', 'zip': '70119', 'country': 'United States', 'contacts': [{'name': 'Sarah Savaski', 'role': 'CONTACT', 'phone': '504-507-2000', 'phoneExt': '63453', 'email': 'sarah.savaski@va.gov'}, {'name': 'David Becnel, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'facility': 'University of Maryland Medical Center', 'status': 'RECRUITING', 'city': 'Baltimore', 'state': 'Maryland', 'zip': '21201', 'country': 'United States', 'contacts': [{'name': 'Van Holden, MD', 'role': 'CONTACT', 'phone': '410-328-8141', 'email': 'vholden@som.umaryland'}, {'name': 'Van Holden, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'facility': 'Boston University Medical Center', 'status': 'RECRUITING', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02118', 'country': 'United States', 'contacts': [{'name': 'Ehab Billatos, MD', 'role': 'CONTACT', 'phone': '617-358-7039', 'email': 'ebillato@bu.edu'}, {'name': 'Ehab Billatos, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'Saint Lukes Hospital', 'status': 'RECRUITING', 'city': 'Kansas City', 'state': 'Missouri', 'zip': '64111', 'country': 'United States', 'contacts': [{'name': 'Matthew Aboudara, MD', 'role': 'CONTACT', 'phone': '816-756-2255', 'email': 'maboudara@saint-lukes.org'}, {'name': 'Matthew Aboudara, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 39.09973, 'lon': -94.57857}}, {'facility': 'Mercy Hospital', 'status': 'RECRUITING', 'city': 'Springfield', 'state': 'Missouri', 'zip': '65804', 'country': 'United States', 'contacts': [{'name': 'Madhu Kalyan Pendurthi, MD MPH', 'role': 'CONTACT', 'phone': '417-820-8161', 'email': 'mpendur1@mercy.net'}, {'name': 'Madhu Kalyan Pendurthi, MD MPH', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 37.21533, 'lon': -93.29824}}, {'facility': 'University of Rochester Medical Center', 'status': 'RECRUITING', 'city': 'Rochester', 'state': 'New York', 'zip': '14642', 'country': 'United States', 'contacts': [{'name': 'Michael Nead, MD, PhD', 'role': 'CONTACT', 'phone': '585-276-7294', 'email': 'Michael_Nead@urmc.rochester.edu'}, {'name': 'Michael Nead, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 43.15478, 'lon': -77.61556}}, {'facility': 'Good Samaritan Cancer Center', 'status': 'NOT_YET_RECRUITING', 'city': 'West Islip', 'state': 'New York', 'zip': '11795', 'country': 'United States', 'contacts': [{'name': 'Stephanie E Solito, MBA, CCRC', 'role': 'CONTACT', 'phone': '631-417-8611', 'email': 'Stephanie.Solito@chsli.org'}, {'name': 'Sharad Chandrika, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 40.70621, 'lon': -73.30623}}, {'facility': 'PulmonIx, LLC', 'status': 'RECRUITING', 'city': 'Greensboro', 'state': 'North Carolina', 'zip': '27401', 'country': 'United States', 'contacts': [{'name': 'Bradley L Icard, DO', 'role': 'CONTACT', 'phone': '336-522-8870', 'email': 'pulmonixresearch@protonmail.com'}, {'name': 'Bradley L Icard, DO', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 36.07264, 'lon': -79.79198}}, {'facility': 'University of Cincinnati', 'status': 'RECRUITING', 'city': 'Cincinnati', 'state': 'Ohio', 'zip': '45267', 'country': 'United States', 'contacts': [{'name': 'Christopher C Radchenko, MD', 'role': 'CONTACT', 'phone': '513-558-4831', 'email': 'radchecr@ucmail.uc.edu'}, {'name': 'Christopher C Radchenko, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'facility': 'Mercy Health St. Vincent Medical Center', 'status': 'RECRUITING', 'city': 'Toledo', 'state': 'Ohio', 'zip': '43608', 'country': 'United States', 'contacts': [{'name': 'Dee Tilley, RN, CCRC', 'role': 'CONTACT', 'phone': '419-251-4919', 'email': 'dee_tilley@mercy.com'}, {'name': 'Vinod Khatri, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 41.66394, 'lon': -83.55521}}, {'facility': 'Ralph H. Johnson VA Health Care System', 'status': 'RECRUITING', 'city': 'Charleston', 'state': 'South Carolina', 'zip': '29401', 'country': 'United States', 'contacts': [{'name': 'Abby Wenzel, PhD', 'role': 'CONTACT', 'phone': '843-789-6965', 'email': 'abby.wenzel@va.gov'}, {'name': 'Nichole T Tanner, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 32.77632, 'lon': -79.93275}}, {'facility': 'VA Caribbean Healthcare', 'status': 'RECRUITING', 'city': 'San Juan', 'zip': '00921-3201', 'country': 'Puerto Rico', 'contacts': [{'name': 'Jose Torres-Palacios, MD', 'role': 'CONTACT', 'phone': '787-641-7582', 'phoneExt': '110116', 'email': 'jose.torres-palacios@va.gov'}, {'name': 'Jose Torres-Palacios, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 18.46633, 'lon': -66.10572}}]}}",,,"{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003074', 'term': 'Solitary Pulmonary Nodule'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}], 'ancestors': [{'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}]}}",False
"{'identificationModule': {'nctId': 'NCT06848699', 'orgStudyIdInfo': {'id': 'HLX43HLX10-ST201'}, 'organization': {'fullName': 'Shanghai Henlius Biotech', 'class': 'INDUSTRY'}, 'briefTitle': 'A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors', 'officialTitle': 'A Phase Ib/ II Clinical Study to Evaluate the Safety ,Torlerbility , and Efficacy of HLX43 (Anti-PD-L1 ADC) in Combination With Serplulimab (Anti-PD-1 Humanized Monocl ) in Patients With Advanced/Metastatic Solid Tumors'}, 'statusModule': {'statusVerifiedDate': '2025-11', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-02-25', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-10-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-10-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-01-22', 'studyFirstSubmitQcDate': '2025-02-21', 'studyFirstPostDateStruct': {'date': '2025-02-27', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-11-14', 'lastUpdatePostDateStruct': {'date': '2025-11-17', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Shanghai Henlius Biotech', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients with advanced/metastatic solid tumors', 'detailedDescription': 'This study is an open-label phase Ib/II clinical study to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in Patients with advanced/metastatic solid tumors. The study is divided into two phases: phase Ib dose escalation and phase II dose expansion.The subjects will receive different dosages of HLX43 combined with a fixed dosage (300 mg) of serplulimab, administered via intravenous infusion every 3 weeks (Q3W) .'}, 'conditionsModule': {'conditions': ['Solid Tumor Cancer', 'Non Small Cell Lung Cancer'], 'keywords': ['HLX43']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 105, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'HLX43 dose 1', 'type': 'EXPERIMENTAL', 'description': 'Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), Until disease progression, initiation of a new anti-tumor therapy, death, emergence of intolerable toxicity, or withdrawal of informed consent (whichever occurs first)', 'interventionNames': ['Drug: HLX43 dose 1', 'Drug: Serplulimab']}, {'label': 'HLX43 dose 2', 'type': 'EXPERIMENTAL', 'description': ': Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), Until disease progression, initiation of a new anti-tumor therapy, death, emergence of intolerable toxicity, or withdrawal of informed consent (whichever occurs first)', 'interventionNames': ['Drug: HLX43 dose 2', 'Drug: Serplulimab']}, {'label': 'HLX43 dose 3', 'type': 'EXPERIMENTAL', 'description': ': Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), Until disease progression, initiation of a new anti-tumor therapy, death, emergence of intolerable toxicity, or withdrawal of informed consent (whichever occurs first)', 'interventionNames': ['Drug: HLX43 dose 3', 'Drug: Serplulimab']}, {'label': 'HLX43 dose 4', 'type': 'EXPERIMENTAL', 'description': ': Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), Until disease progression, initiation of a new anti-tumor therapy, death, emergence of intolerable toxicity, or withdrawal of informed consent (whichever occurs first)', 'interventionNames': ['Drug: HLX43 dose 4', 'Drug: Serplulimab']}, {'label': 'HLX43 dose 5', 'type': 'EXPERIMENTAL', 'description': 'Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), Until disease progression, initiation of a new anti-tumor therapy, death, emergence of intolerable toxicity, or withdrawal of informed consent (whichever occurs first)', 'interventionNames': ['Drug: HLX43 dose 5', 'Drug: Serplulimab']}], 'interventions': [{'type': 'DRUG', 'name': 'HLX43 dose 1', 'description': 'HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.', 'armGroupLabels': ['HLX43 dose 1']}, {'type': 'DRUG', 'name': 'HLX43 dose 2', 'description': 'HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.', 'armGroupLabels': ['HLX43 dose 2']}, {'type': 'DRUG', 'name': 'HLX43 dose 3', 'description': 'HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.', 'armGroupLabels': ['HLX43 dose 3']}, {'type': 'DRUG', 'name': 'HLX43 dose 4', 'description': 'HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.', 'armGroupLabels': ['HLX43 dose 4']}, {'type': 'DRUG', 'name': 'HLX43 dose 5', 'description': 'HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.', 'armGroupLabels': ['HLX43 dose 5']}, {'type': 'DRUG', 'name': 'Serplulimab', 'description': 'anti-PD-1 humanized monoclonal antibody injection', 'armGroupLabels': ['HLX43 dose 1', 'HLX43 dose 2', 'HLX43 dose 3', 'HLX43 dose 4', 'HLX43 dose 5']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'DLT', 'description': 'The proportion of subjects experiencing dose-limiting toxicity (DLT) events in each dosage group during the DLT observation period', 'timeFrame': '21 days after the first dose'}, {'measure': 'MTD', 'description': 'The maximum tolerated dose of HLX43 incombination with serplulimab', 'timeFrame': 'through study completion, an average of 12 months'}, {'measure': 'ORR', 'description': 'Objective response rate (ORR) (assessed by the IRRC according to the RECIST v1.1 criteria)', 'timeFrame': 'up to 24 weeks'}], 'secondaryOutcomes': [{'measure': 'Incidence and severity of adverse events (AEs)', 'description': 'severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events \\[NCI CTCAE\\] Version \\[v\\] 5.0', 'timeFrame': 'from the date of the first dose to to 90 days after the last dose or the initiation of another anticancer treatment (whichever occurs first).'}, {'measure': 'RP2/3D', 'description': 'RP2/3D of HLX43 combined with serplulimab in NSCLC patients', 'timeFrame': 'through study completion, an average of 12 months'}, {'measure': 'PFS', 'description': 'Defined as the time (in months) from randomization to the first confirmed and documented progressive disease or death (whichever occurs first) as assessed by the IRRC according to the RECIST v1.1 criteria.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 15 months'}, {'measure': 'PFS', 'description': 'Defined as the time (in months) from randomization to the first confirmed and documented progressive disease or death (whichever occurs first) as assessed by INV according to the RECIST v1.1 criteria.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 15 months'}, {'measure': 'ORR', 'description': 'Objective response rate (ORR) (assessed by INV according to the RECIST v1.1 criteria)', 'timeFrame': 'up to 24 week'}, {'measure': 'OS', 'description': 'Overall Survival', 'timeFrame': 'From randomization to death from any cause (up to approximately 25 months)'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Voluntarily participate in the clinical trial; fully understand and be informed about this study and sign the Informed Consent Form (ICF); be willing and able to comply with and complete all trial procedures;\n2. Age at the time of signing the ICF is ≥ 18 years and ≤ 75 years;\n3. Phase Ib enrollment of patients with histologically or cytologically confirmed advanced /metastatic solid tumor who have experienced treatment failure or for whom no standard treatment is available;Phase II enrollment includes advanced /metastatic NSCLC subjects confirmed by histology or cytology, requiring the presence of EGFR mutation and failure or intolerance to EGFR-TKI or/and platinum-based chemotherapy.\n4. Within 4 weeks prior to the first dose, at least one measurable lesion assessed by the investigator according to RECIST 1.1;\n5. Subjects must provide qualified tumor tissue samples for the determination of PD-L1 expression levels.\n6. The ECOG PS score within 7 days prior to the first use of the Investigational Product is 0 or 1;\n7. Expected survival ≥ 12 weeks;\n8. Major organ functions are normal, meeting the following criteria (within 14 days prior to the first administration in this study, no transfusion, albumin, recombinant human thrombopoietin, or colony-stimulating factor (CSF) treatment was received):\n9. Female subjects of childbearing potential must meet the following criteria:\n\n   a)The blood pregnancy test must be negative within 7 days prior to the first administration of the medication; b)Agree to use at least one highly effective method of contraception during the trial period and for at least 6 months after the last administration of the drug;c)Breastfeeding is contraindicated.\n10. Male subjects must meet the following criteria: agree to use at least one highly effective method of contraception during the trial and for at least 6 months after the last dose.\n\nExclusion Criteria:\n\n1. History of any second malignancy within 3 years prior to randomization, except for early-stage malignancies (carcinoma in situ or stage I tumors) that have received radical treatment, such as non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer, ductal carcinoma in situ of the breast, and papillary thyroid carcinoma.\n2. Previously experienced ≥ Grade 3 immune-related Adverse Events during immunotherapy.\n3. Pleural effusion or pericardial effusion, or ascites requiring clinical intervention as determined by the investigator;\n4. Subjects with clinical symptoms of brain metastases, spinal cord compression, meningitis carcinomatosa, or other evidence indicating that brain or spinal cord metastatic lesions are not yet controlled; Note: Subjects with asymptomatic or stable brain metastases, spinal cord compression, or meningitis carcinomatosa as determined by theinvestigator may be eligible for enrollment;\n5. Subjects with a history or current condition of interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, or severe impairment of pulmonary function, as determined by the sub investigator, that may interfere with the detection and management of suspected drug-related pulmonary toxicity;\n6. The subject has poorly controlled cardiovascular and cerebrovascular clinical symptoms or diseases, including but not limited to: (1) NYHA class II or higher heart failure or left ventricular ejection fraction (LVEF) \\<50%; (2) unstable angina; (3) myocardial infarction or cerebrovascular accident within the past 6 months (excluding lacunar infarction, minor cerebral ischaemia, or transient ischaemic attack); (4) uncontrolled arrhythmia (including QTc interval ≥450 ms for males and ≥470 ms for females, with QTc interval calculated using the Fridericia formula); (5) poorly controlled hypertension (systolic blood pressure \\>150 mmHg and/or diastolic blood pressure \\>100 mmHg despite active treatment);\n7. History of immunodeficiency diseases, including testing positive for human immunodeficiency virus (HIV), or having other acquired or congenital immunodeficiency diseases, or a history of organ transplant;\n8. Has active pulmonary tuberculosis;\n9. Subjests with active HBV, HCV infection or co-infection;\n10. There is a known active or suspected autoimmune disease. Enrollment is allowed for subjects in a stable condition who do not require systemic immunosuppressive therapy.\n11. Subjects requiring systemic corticosteroids (\\>10 mg/day prednisone therapeutic dosage) or other immunosuppressive drug therapy within 14 days prior to the first administration of the Investigational Product or during the study. However, the following situations allow for enrollment: in the absence of active autoimmune disorders, the use of topical external application or inhaled steroids and adrenal hormone replacement therapy at a dosage ≤10 mg/day prednisone therapeutic dosage is permitted; prophylactic medication is allowed.\n12. Any active infection requiring systemic anti-infective therapy within 14 days prior to the first administration of the Investigational Product;\n13. Within 28 days prior to the first administration of the Investigational Product, the subject has undergone major surgery. In this study, major surgery is defined as a procedure requiring at least 3 weeks of postoperative recovery before being eligible to receive treatment in this study. Tumor paracentesis or lymph node incisional biopsy is permitted for enrollment.\n14. Strong inhibitors or strong inducers of CYP2D6 or CYP3A were used within 2 weeks prior to the first administration of the drug.\n15. Received live viral vaccine treatment within 28 days prior to the first administration of the Investigational Product; however, inactivated viral vaccines for seasonal flu and novel coronavirus are permitted;\n16. Participating in another clinical trial or planning to start this study with less than 14 days since the end-of-therapy of the previous clinical trial; less than 5 half-lives since the last course of anti-tumor therapy;\n17. Known to have a severe allergy to any monoclonal antibody;\n18. Subjects who are not suitable for participating in this clinical study due to any clinical or laboratory abnormalities or other reasons as assessed by the investigator.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Bo Zhu, Dr', 'role': 'CONTACT', 'phone': '86-023-68755626', 'email': 'bo.zhu@tmmu.edu.cn'}], 'locations': [{'facility': 'Hunan Provincial Cancer Hospital', 'status': 'RECRUITING', 'city': 'Hunan', 'state': 'Changsha', 'zip': '410031', 'country': 'China', 'contacts': [{'name': 'Lin Wu, Dr', 'role': 'CONTACT', 'phone': '0731-89766300', 'email': 'wulin-calf@vip.163.com'}, {'name': 'Lin Wu, Dr', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 28.71667, 'lon': 118.83333}}, {'facility': 'Shandong Cancer Hospital', 'status': 'RECRUITING', 'city': 'Jinan', 'state': 'Shangdong', 'country': 'China', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}}, {'facility': 'Second Affiliated Hospital of Army Medical University, PLA', 'status': 'RECRUITING', 'city': 'Chongqing', 'zip': '400000', 'country': 'China', 'contacts': [{'name': 'Bo Zhu, Dr', 'role': 'CONTACT'}], 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}]}}",,,"{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}}",False
"{'identificationModule': {'nctId': 'NCT07083687', 'orgStudyIdInfo': {'id': 'HNCH-2025KY34'}, 'organization': {'fullName': 'Hunan Cancer Hospital', 'class': 'OTHER'}, 'briefTitle': 'Lorlatinib in ROS1+ NSCLC With Brain Metastasis', 'officialTitle': 'A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib in TKI naïve, Advanced ROS1-Positive Non-Small Cell Lung Cancer Patients With Brain Metastases'}, 'statusModule': {'statusVerifiedDate': '2025-07', 'overallStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-08-15', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2027-01-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2028-12-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-06-27', 'studyFirstSubmitQcDate': '2025-07-16', 'studyFirstPostDateStruct': {'date': '2025-07-24', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-07-16', 'lastUpdatePostDateStruct': {'date': '2025-07-24', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Hunan Cancer Hospital', 'class': 'OTHER'}}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': True}, 'descriptionModule': {'briefSummary': 'The goal of this Phase II, multicenter, open-label, single-arm clinical trial is to evaluate the intracranial efficacy and safety of lorlatinib in adults with TKI-naïve, advanced ROS1-positive non-small cell lung cancer (NSCLC) and untreated brain metastases. The main questions it aims to answer are:\n\nWhat is the intracranial efficacy (eg., objective response rate/PFS) assessed by revised RECIST v1.1?\n\nHow do exploratory biomarkers (e.g., ctDNA dynamics in plasma/CSF) correlate with lorlatinib resistance?\n\nParticipants will:\n\nReceive lorlatinib 100 mg orally once daily until disease progression or unacceptable toxicity.\n\nUndergo brain MRI/CT scans every 8 weeks (first 12 cycles) and every 16 weeks thereafter.\n\nProvide blood samples for safety/biomarker analysis and optional CSF samples via lumbar puncture during scheduled visits.'}, 'conditionsModule': {'conditions': ['Lung Cancer (NSCLC)'], 'keywords': ['non-small cell lung cancer', 'ROS1', 'lorlatinib']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 21, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': '100mg lorlatinib QD Orally', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: Lorlatinib 100 mg']}], 'interventions': [{'type': 'DRUG', 'name': 'Lorlatinib 100 mg', 'description': 'After enrollment, patients will receive 100 mg of lorlatinib orally once daily until disease progression, unacceptable toxicity, or withdraw study .', 'armGroupLabels': ['100mg lorlatinib QD Orally']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Intracranial Objective Response Rate (iORR), based on the modified version 1.1 of the Response Evaluation Criteria in Solid Tumors (RECIST)', 'timeFrame': 'up to 26 weeks'}]}, 'eligibilityModule': {'eligibilityCriteria': ""Inclusion Criteria:\n\n1. Age≥18 years old.\n2. Histologically or cytologically confirmed diagnosis of ROS1+ NSCLC with brain metastases before the use of lorlatinib.\n3. ROS1 rearrangement positive confirmed by IHC FISH, PCR, or next generation sequencing (NGS). Patients with other treatable gene mutations besides ROS1 need to submit for discussion with the study experts to determine eligibility.\n4. Treatment naïve or one prior systemic treatment with platinum-based chemotherapy.\n5. Imaging (MR/CT) confirmed untreated brain metastases before lorlatinib initiation;\n6. Participants with asymptomatic brain metastases or currently unrequiring corticosteroid treatment, or on a stable or decreasing dose of ≤10 mg QD prednisone or equivalent can be enrolled.\n7. According to RECIST 1.1, patients must have at least one at least one measurable intracranial target lesion with the long axis greater or equal to 5 mm at baseline.\n8. Eastern Cooperative Oncology Group Performance (ECOG) score of 0-1.\n9. The subject's expected survival time must be 12 weeks or longer.\n10. Participants must have normal primary organ function and meet the following criteria during screening:\n\n（1）No blood transfusions within the past 14 days and Adequate hematopoietic function, defined as follows:\n\na） Hemoglobin \\> 90g/L（without the use of erythropoietin within the past 14 days） b） Absolute Neutrophil Count (ANC) ≥1.5×109/L（without the use of growth factors within the past 14 days） c） Platelets（PLT）≥100×109/L（without the use of platelet-stimulating agents within the past 14 days） （2）Adequate Liver Function, defined as follows：\n\n1. Total serum bilirubin ≤1.5 x upper limit of normal (ULN)\n2. Alanine Aminotransferase（ALT） and Aspartate Aminotransferase（AST）≤3.0 x ULN (≤5.0 x ULN in case of liver metastases) （3）Adequate Renal Function, defined as follows：\n\na） Serum creatinine（Cr）≤1.5× ULN or estimated creatinine clearance（CCr）≥45 ml/min （4）Adequate coagulation function, defined as follows：\n\na） International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN; PT can be within the predetermined range for the anticoagulant if the participant is currently receiving anticoagulant therapy Adequate Pancreatic Function, defined as serum total amylase≤1.5×ULN； 11.Adequate Pancreatic Function, defined as serum total amylase≤1.5×ULN； For women of childbearing potential (defined as not being postmenopausal for at least 1 year, or having undergone surgical sterilization or hysterectomy), a serum pregnancy test should be conducted within seven days prior to the first administration of the investigational drug, and the result should be negative. All participants (regardless of gender) must agree to use contraceptive measures during the entire treatment period and for at least 90 days after the last dose of the investigational drug.\n\n12.Participants must understand and voluntarily sign the written informed consent form, demonstrate good compliance, adhere to the trial treatment plan and visit schedule, and be able to cooperate in observing adverse events and treatment efficacy.\n\nExclusion Criteria:\n\n1. Have received treatment with the investigational drug or known allergy to the ingredients or excipients of the investigational drug.\n2. Concurrent participation in another clinical study, except for observational (non-interventional) clinical studies or subsequent stages of interventional studies.\n3. Brain metastasis combined with leptomeningeal metastases.\n4. Brain metastasis with bleeding, or the presence of central nervous system complications requiring urgent local intervention (such as surgery, radiotherapy, etc.).\n5. Presence of spinal cord compression unless pain symptoms and neurological function have remained stable or improved 2 weeks prior to enrollment.\n6. Received open surgery (except surgery for biopsy purposes) within ≤14 days prior to enrollment.\n7. Received intracranial radiotherapy before enrollment.\n8. Fever with a temperature above 38℃ within the past week; or clinically significant bacterial, fungal, or viral infection, including but not limited to HIV infection, active HCV infection, active tuberculosis, active hepatitis B (active hepatitis B is defined as HBsAg positive and HBV-DNA copy number exceeds the upper limit of normal in the laboratory of the study center); or infections requiring hospitalization, septicemia, severe pneumonia, etc.\n9. Significant clinical abnormalities in rhythm, conduction, or morphology on resting ECG, such as QT interval (QTc) ≥ 450 ms in males or ≥ 470 ms in females, complete left bundle branch block, 2nd degree or higher heart block, clinically significant ventricular arrhythmia, or atrial fibrillation.\n10. Unstable angina, congestive heart failure (NYHA class III or IV), myocardial infarction, coronary/peripheral artery bypass, cerebrovascular accident, untreated transient ischemic attack, or symptomatic pulmonary embolism occurring currently or within the past 3 months.\n11. Presence of risk factors for QT interval prolongation or increased risk of arrhythmia, such as grade 2 hypokalemia (grade 2 hypokalemia is defined as: blood potassium \\< normal lower limit -3.0mmol/L, and with symptoms, requiring treatment), congenital long QT syndrome, family history of long QT syndrome.\n12. Past or current clinically active interstitial lung disease; presence of pulmonary interstitial fibrosis or active tuberculosis.\n13. Disorders of swallowing function, active gastrointestinal disease, or other diseases significantly affecting the absorption, distribution, metabolism, and excretion of the investigational drug. History of major gastric resection.\n14. Presence of other acquired, congenital immunodeficiency diseases, or previous solid organ or hematopoietic stem cell transplantation.\n15. Evidence of severe or uncontrolled systemic diseases (such as severe mental, neurological diseases, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, liver or kidney diseases, uncontrolled hypertension i.e., still being greater than or equal to CTCAE 5.0 grade 3 hypertension after drug treatment).\n16. Diagnosis or treatment of other malignant tumors within the past 5 years (excluding adequately treated basal cell or squamous cell skin cancer, bladder carcinoma in situ, cervical carcinoma in situ, ductal carcinoma in situ, localized prostate cancer).\n17. Use of any known QT-prolonging drugs within 2 weeks before the first dose.\n18. Use or consumption of known potent CYP3A4 inhibitors in medications or food within the past 2 weeks; use of known potent CYP3A4 inducers within the past 2 weeks; use of medications that act as CYP3A4 substrates (with a narrow therapeutic index) within the past 2 weeks.\n19. Severe acute or chronic mental illness, including recent (within the past year) or active suicidal ideation or behavior.\n20. For pregnant or lactating women or male or female participants with reproductive potential, refusal to adopt effective contraceptive measures during the treatment period and for 90 days after the last use of the investigational drug.\n21. The investigator believes that the participant may be unable to complete the study or comply with the study requirements.\n22. The investigator believes that there are other potential risks making the participant unsuitable for this study."", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Lin Wu', 'role': 'CONTACT', 'phone': '13170419973', 'email': 'wulin-calf@vip.163.com'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}}",,,"{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000590786', 'term': 'lorlatinib'}]}}",False
"{'identificationModule': {'nctId': 'NCT05930665', 'orgStudyIdInfo': {'id': 'AK104-IIT-028'}, 'organization': {'fullName': 'Sun Yat-sen University', 'class': 'OTHER'}, 'briefTitle': 'Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma', 'officialTitle': 'A Phase II, Prospective, Single Arm Trial of Cadonilimab in Combination With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma'}, 'statusModule': {'statusVerifiedDate': '2024-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-11-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-07', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-07', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-06-26', 'studyFirstSubmitQcDate': '2023-07-03', 'studyFirstPostDateStruct': {'date': '2023-07-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-19', 'lastUpdatePostDateStruct': {'date': '2024-02-21', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Wenfeng Fang', 'investigatorTitle': 'chief physician', 'investigatorAffiliation': 'Sun Yat-sen University'}, 'leadSponsor': {'name': 'Sun Yat-sen University', 'class': 'OTHER'}}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of cadonilimab in combination with bevacizumab and standard chemotherapy as first Line therapy in unresectable pleural mesothelioma.'}, 'conditionsModule': {'conditions': ['Pleural Mesothelioma'], 'keywords': ['bispecific antibody']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 38, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin', 'type': 'EXPERIMENTAL', 'description': 'Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin for 4 to 6 cycles, followed by Maintenance with Cadonilimab and Bevacizumab', 'interventionNames': ['Drug: Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin']}], 'interventions': [{'type': 'DRUG', 'name': 'Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin', 'description': 'Cadonilimab 10mg/kg intravenous (IV) every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks + Carboplatin AUC 5 IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Cadonilimab 10mg/kg IV every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks', 'armGroupLabels': ['Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin'], 'otherNames': ['AK104']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Objective Response Rate (ORR)', 'description': 'defined as the percentage of participants who achieve a best overall response of complete response or partial response assessed according to mRECIST v1.1 for assessment of response in malignant pleural mesothelioma.', 'timeFrame': 'Up to 36 months'}], 'secondaryOutcomes': [{'measure': 'Progression Free Survival (PFS)', 'description': 'defined as the time between the date of first dose of study drug and the date of first documented tumor progression per mRECIST v1.1, or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to 36 months'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'defined as the percentage of participants who achieve a best overall response of complete response, partial response, or stable disease assessed according to mRECIST v1.1 for assessment of response in malignant pleural mesothelioma.', 'timeFrame': 'Up to 36 months'}, {'measure': 'Duration of Response (DoR)', 'description': 'defined as the interval from the date of first documentation of objective response (complete response or partial response, according to the mRECIST v1.1) to the date of first documented tumor progression, or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to 36 months'}, {'measure': 'Overall Survival (OS)', 'description': 'defined as the time between the date of first dose of study drug and the date of death due to any cause.', 'timeFrame': 'Up to 36 months'}, {'measure': 'Adverse Events (AEs)', 'timeFrame': 'Up to 36 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Key Inclusion Criteria:\n\n1. Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery\n2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n3. No previous systemic anti-tumor treatment for advanced/metastatic disease\n4. Measurable disease as per mRECIST v1.1 for assessment of response in malignant pleural mesothelioma.\n5. Adequate haematological, renal and liver function.\n\nKey Exclusion Criteria:\n\n1. Primitive peritoneal, pericardial and tunica vaginalis testis mesothelioma.\n2. Active, untreated central nervous system (CNS) metastasis.\n3. Use of Chinese herbal medicine or immunomodulatory agents with anti-tumor indications within 14 days prior to the first dose of study treatment.\n4. Known active autoimmune diseases.\n5. Presence of other uncontrolled serious medical conditions.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Wenfeng Fang, MD', 'role': 'CONTACT', 'phone': '+86-15322302066', 'email': 'fangwf@sysucc.org.cn'}], 'locations': [{'facility': 'Sun Yat-sen University Cancer Center', 'status': 'RECRUITING', 'city': 'Guangzhou', 'state': 'Guangdong', 'country': 'China', 'contacts': [{'name': 'Wenfeng Fang, MD', 'role': 'CONTACT', 'phone': '+86-15322302066', 'email': 'fangwf@sysucc.org.cn'}], 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}]}}",,,"{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000086002', 'term': 'Mesothelioma, Malignant'}], 'ancestors': [{'id': 'D008654', 'term': 'Mesothelioma'}, {'id': 'D000236', 'term': 'Adenoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D018301', 'term': 'Neoplasms, Mesothelial'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D010997', 'term': 'Pleural Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}}",False
"{'identificationModule': {'nctId': 'NCT04130516', 'orgStudyIdInfo': {'id': 'LNS-101'}, 'secondaryIdInfos': [{'id': 'MK3475-B47', 'type': 'OTHER', 'domain': 'Merck, Sharpe and Dohme, LLC'}, {'id': 'KEYNOTE-B47', 'type': 'OTHER', 'domain': 'Merck, Sharpe and Dohme, LLC'}], 'organization': {'fullName': 'Linnaeus Therapeutics, Inc.', 'class': 'INDUSTRY'}, 'briefTitle': 'Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab', 'officialTitle': 'A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab'}, 'statusModule': {'statusVerifiedDate': '2025-12', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2019-10-21', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-12-15', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2019-10-10', 'studyFirstSubmitQcDate': '2019-10-15', 'studyFirstPostDateStruct': {'date': '2019-10-17', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-12-16', 'lastUpdatePostDateStruct': {'date': '2025-12-18', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Linnaeus Therapeutics, Inc.', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Merck Sharp & Dohme LLC', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combination with pembrolizumab. The study will include a dose escalation phase, a dose expansion phase, and phase 2A cohorts. Up to 200 patients will be accrued for this study. Up to 15 study sites in the United States will participate in the study.', 'detailedDescription': 'In this Phase 1/2, first-in-human, open-label, multi-center study. Dose escalation cohorts enrolled at least 3 patients in accordance with a traditional dose escalation 3+3 design, and the study will determine the MTD/RP2D of LNS8801. LNS8801 will be administered orally 3 days/week or once or twice a day during 21 day cycles until disease progression or unacceptable toxicity occurs.\n\nSafety assessments will be performed on all patients at screening, throughout their participation in the study, and for 30 days (90 days in combination cohorts) following the last dose of study drug. Throughout the study, imaging of tumors for evidence of tumor response and/or progression will be performed; biopsies will be performed on accessible lesions.\n\nAfter the RP2D of LNS8801 is identified and the safety of dosing LNS8801 with pembrolizumab has been established, expansion cohorts and Phase 2A cohorts will open. Any 2 dose escalation cohorts may be expanded to 8 to 10 patients to include additional patients to further explore PK and PD.\n\nPhase 1B expansion cohorts include a monotherapy cohort (LNS8801 alone) of melanoma patients (not uveal) who are now not eligible for additional anti-PD-1 therapy in the judgement of the investigator because of prior severe immune related adverse events and a combination therapy (LNS8801 + pembrolizumab) cohort in anti-PD-1/L1 refractory advanced cancer patients who have previously had clinical benefit on anti-PD-1/L1 therapy alone or in combination (complete response or partial response of any duration, or confirmed stable disease for at least 16 weeks) but have since relapsed and not had an intervening cytotoxic chemotherapy. Up to 28 evaluable patients may be studied in each cohort.\n\nThe study will also include the following 8 Phase 2A cohorts.\n\nMonotherapy with 125 mg LNS8801 PO:\n\nCOHORT M2: up to 20 evaluable patients with no remaining SOC therapies with pancreatic, gastric, non small cell lung cancer (NSCLC) or colorectal cancers.\n\nCOHORT M3: up to 10 evaluable patients with no remaining SOC therapies with advanced malignant cutaneous melanoma having received as their immediate prior line of therapy a PD-1/L1 targeted immune checkpoint inhibitor (IO), alone or in combination, and who are now not eligible for anti-PD-1 treatment in the judgement of the Investigator due to prior severe immune related adverse events.\n\nCOHORT M4: up to 10 patients with advanced solid tumor malignancies and no remaining SOC therapies, other than cutaneous melanoma, having received as their immediate prior line of therapy a PD-1/L1 targeted immune checkpoint inhibitor (IO), alone or in combination, and having been forced to discontinue IO therapy due to an immune-related adverse event (irAE).\n\nCOHORT M5: up to 10 evaluable patients with metastatic uveal melanoma and no remaining SOC therapies that have 2 or fewer prior lines of systemic therapy.\n\nCombination therapy cohorts treated with 125 mg LNS8801 daily PO + 200 mg Q3W Pembrolizumab IV:\n\nCOHORT C2: up to 20 evaluable patients with no remaining SOC therapies with pancreatic, gastric, non small cell lung cancer (NSCLC) or colorectal cancers.\n\nCOHORT C3: up to 10 evaluable patients with metastatic non-small cell lung cancer (NSCLC) expressing PD-L1 (Tumor Proportion Score \\[TPS\\] ≥1% and ≤49%) as determined by an FDA-approved test will be treated with the combination of LNS8801 plus pembrolizumab. Eligible patients must either have no EGFR or ALK genomic tumor aberrations or have not demonstrated disease response on or following FDA-approved therapy for these aberrations. Inclusion and exclusion criteria will otherwise be consistent with those criteria specified above.\n\nCOHORT C5: up to 10 evaluable patients with metastatic uveal melanoma and no remaining SOC therapies that have 2 or fewer prior lines of systemic therapy.\n\nCOHORT C6: up to 10 evaluable patients with advanced malignant cutaneous melanoma and no remaining SOC therapies.\n\nUp to 200 patients will be accrued for this study at up to 15 study sites in the United States.'}, 'conditionsModule': {'conditions': ['Solid Tumor, Adult'], 'keywords': ['Melanoma, Uveal Melanoma, NSCLC, Colorectal, Pancreatic, and Gastric Cancers']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 200, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Active', 'type': 'OTHER', 'description': 'Phase 1/2 open-label', 'interventionNames': ['Drug: LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER', 'Biological: Pembrolizumab - anti-PD-1 antibody']}], 'interventions': [{'type': 'DRUG', 'name': 'LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER', 'description': 'LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER', 'armGroupLabels': ['Active']}, {'type': 'BIOLOGICAL', 'name': 'Pembrolizumab - anti-PD-1 antibody', 'description': 'pembrolizumab- anti-PD-1 antibody', 'armGroupLabels': ['Active'], 'otherNames': ['KEYTRUDA®', 'Pembrolizumab']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Adverse events observed for LNS8801 dosed alone and in combination with pembrolizumab', 'timeFrame': 'Duration of study, approximately 24 months'}], 'secondaryOutcomes': [{'measure': 'LNS8801 plasma exposure (AUC) as a function of dose', 'description': 'AUC0-end', 'timeFrame': 'During first 23 days of dosing'}, {'measure': 'LNS8801 plasma exposure (Cmax) as a function of dose', 'description': 'Cmax', 'timeFrame': 'During the first 23 days of dosing'}, {'measure': 'LNS8801 plasma exposure (t1/2) as a function of dose', 'description': 'T1/2', 'timeFrame': 'During the first 23 days of dosing'}]}, 'eligibilityModule': {'eligibilityCriteria': ""Prescreening Inclusion Criteria for genotyping:\n\n1. Has histopathologically confirmed locally advanced or metastatic solid tumor cancer.\n2. Is able to understand and voluntarily sign a written informed consent form and is willing and able to comply with protocol requirements.\n3. Is considered likely to meet the detailed inclusion and exclusion criteria for treatment when required.\n\nInclusion Criteria for treatment portion of study:\n\n1. Has histopathologically confirmed locally advanced or metastatic solid tumor cancer (or lymphoma in Phase 1). The solid tumor cancer is further defined in some cohorts as:\n\n   1. Phase 1B monotherapy expansion cohort:\n\n      Has melanoma, except uveal melanoma, and has previously received anti-PD-1/L1 therapy and is now not eligible for anti-PD-1 treatment in the judgement of the Investigator due to prior severe immune related adverse events, and has not received intervening cancer therapy since the anti-PD-1/L1 therapy.\n   2. Monotherapy Cohort M2:\n\n      Has pancreatic, gastric, non small cell lung cancer (NSCLC), or colorectal cancer.\n   3. Monotherapy Cohort M3:\n\n      Has cutaneous melanoma, and has previously received anti-PD-1/L1 therapy and is now not eligible for anti-PD-1 treatment in the judgement of the Investigator due to prior severe immune related adverse events, and has not received intervening cancer therapy since the anti-PD-1/L1 therapy.\n   4. Monotherapy Cohort M4:\n\n      Has any solid tumor malignancy, except cutaneous melanoma, and has previously received anti-PD-1/L1 therapy and is now not eligible for anti-PD-1 treatment in the judgement of the Investigator due to prior severe immune related adverse events, and has not received intervening cancer therapy since the anti-PD-1/L1 therapy.\n   5. Monotherapy Cohort M5:\n\n      Has metastatic uveal melanoma, and has received ≤ 2 prior lines of prior systemic therapy.\n   6. Phase 1B combination expansion cohort:\n\n      Has any locally advanced or metastatic solid tumor cancer, and has first had a clinical benefit from, followed by documented disease progression on an anti-PD-1/L1 treatment administered either as monotherapy or in combination. Clinical benefit is defined as a complete or partial response of any duration or stable disease for at least 16 weeks with at least one scan showing stable disease. Patients should not have received intervening therapy that did not include anti-PD1/L1 between finishing anti-PD-1/L1 treatment and commencing study treatment.\n\n      Disease progression on an anti-PD-1/L1 therapy is defined as both:\n      1. Having received anti-PD-1/L1 therapy at least twice if dosed every 4 weeks (q4w) or longer, at least 3 times if dosed every 3 weeks (q3w), or at least 4 times if dosed every 2 weeks (q2w) and,\n      2. Having documented clinical or radiographic progression of disease (PD) while on anti-PD-1/L1 therapy.\n   7. Combination Therapy Cohort C2:\n\n      Has pancreatic, gastric, NSCLC, or colorectal cancer.\n   8. Combination Therapy Cohort C3:\n\n      Has metastatic NSCLC expressing PD-L1 with a Tumor Proportion Score (TPS) ≥1% and ≤49% as determined by an FDA-approved test, and must not have EGFR or ALK genomic tumor aberrations or have demonstrated disease response on or following FDA-approved therapy for these aberrations, and is PD-1/L1 naïve, and is eligible for pembrolizumab as the standard of care or has no available standard of care.\n   9. Combination Therapy Cohort C5:\n\n      Has metastatic uveal melanoma and, has received ≤ 2 prior lines of prior systemic therapy.\n   10. Combination Therapy Cohort C6:\n\n   Has cutaneous melanoma.\n2. Has no standard of care or the patient declines standard of care options.\n\n   a. An exception to this is metastatic NSCLC patients expressing PD-L1 with a Tumor Proportion Score (TPS) ≥1% and ≤49% who may enter Phase 2 pembrolizumab Combination Therapy Cohort C3 with anti-PD-1 therapy as their standard of care.\n3. Has measurable disease per RECIST v1.1 or RANO as assessed by the local site investigator/radiologist. Lesions in a previously irradiated area are measurable if progression has been demonstrated after radiation. Lesions must be measurable in at least 2 dimensions in a spiral CT scan or MRI. For lymphoma patients only, the minimum measurement must be \\>15 mm on the long axis and \\>10 mm on the short axis.\n\n   a. Patients with RECIST target lesions in bones must have a PET scan between their last cancer therapy and Cycle 1 Day 1.\n4. Be at least18 years of age on day of signing informed consent.\n5. Have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n6. Have an estimated life expectancy of \\>3 months.\n7. Patients who have surgically accessible lesions should agree to biopsies from nonirradiated tumor lesions or irradiated tumor lesions that have shown progression since irradiation. For the avoidance of doubt, if no surgically accessible lesions exist or a biopsy is contraindicated, patients may still enter the study.\n8. Be able to swallow capsules and tablets.\n9. Have adequate organ and bone marrow function defined by:\n\n   1. Absolute neutrophil count \\>=1.5 × 109/L (\\>=1500/mm3).\n   2. Hemoglobin \\>=9.0 g/dL or equivalent. Criteria must be met without packed red blood cell transfusion within the prior 2 weeks. Participants can be on a stable dose of erythropoietin (≥ 3 months).\n   3. Platelet count \\>=75 × 10e9/L (\\>=75,000/mm3) for LNS8801 monotherapy cohorts Platelet count \\>=100 × 10e9/L (\\>=100,000/mm3) for LNS8801/pembrolizumab combination cohorts.\n   4. Total bilirubin \\<=1.5 × institutional upper limit of normal (ULN), unless known Gilbert syndrome has been diagnosed.\n   5. Measured or calculated creatinine clearance (glomerular filtration rate) \\>=50 mL/min/1.73 m2.\n   6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\<=2.5 × ULN or \\<=5 × ULN with cancer in the liver.\n   7. For cohorts receiving LNS8801/pembrolizumab combination therapy, prothrombin time (PT) or activated partial thromboplastin time (aPTT) must be ≤1.5 × ULN. If a participant is receiving anticoagulant therapy, PT or aPTT must be within therapeutic range of intended use of anticoagulants.\n10. Female patients of childbearing potential must have a negative serum pregnancy test at screening and a negative (serum or urine) pregnancy test within 72 hours before the first dose of study drug. If the urine test is positive or cannot be confirmed negative, a serum pregnancy test will be required and must be negative for the patient to be eligible.\n11. Female patients must not be breastfeeding.\n12. Female patients of childbearing potential must be willing to use a highly effective contraception method prior to study entry, while on study drug, and for a period of at least 4 months following the last dose of study drug.\n\n    Note: Women receiving estrogen-based contraceptives will be excluded from the study.\n\n    Note: A woman is considered of childbearing potential unless she is postmenopausal (\\>1 year without menses and confirmed with a follicle-stimulating hormone test) or surgically sterilized via bilateral oophorectomy, hysterectomy, bilateral tubal ligation, or successful Essure® placement with a documented confirmation test at least 3 months after the procedure.\n\n    Male patients must be surgically sterile or willing to use a highly effective double-barrier contraception method (eg, male condom with diaphragm or male condom with cervical cap) upon study entry, while on study drug, and for a period of at least 4 months following the last dose of study drug. Males must agree to refrain from donating sperm during this period.\n13. Highly effective contraception is defined as a method of contraception that has a \\<1% failure rate when used consistently and correctly (as defined by the International Council for Harmonization Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Research M3 \\[R2\\]). These methods include implants, injectables, combined hormonal contraceptives (eg, combined oral contraceptives \\[excluding estrogen-based contraceptives\\], patch, and vaginal ring), some intrauterine devices (IUDs) (eg, IUD or intrauterine system), sexual abstinence, or a monogamous relationship with a vasectomized partner.\n\n    a. True abstinence, when in line with the preferred and usual lifestyle of the patient, is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drug (ie, 60 days after discontinuing study drug or 5 times the terminal elimination half-life, whichever is longer). Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\n14. Be able to understand and voluntarily sign a written informed consent form and is willing and able to comply with protocol requirements.\n\nExclusion Criteria for Treatment Portion of Study:\n\n1. Has thyroid cancer or gall bladder cancer (excluded from Phase 1 cohorts only).\n2. Has any cancer that is known to be estrogen receptor-positive (ERalpha+).\n3. Received an anticancer therapy within 4 weeks (6 weeks for nitrosoureas, mitomycin C, or pembrolizumab given on a 6-week cycle) or 5 half-lives, whichever is shorter, before the first dose of study drug. Except in anti-PD-1/L1 refractory cohorts, where patients may start LNS8801 therapy at what would be the beginning of the next cycle of their immunotherapy cycle (eg, LNS8801 may be dosed 3 or 6 weeks after the last dose of pembrolizumab depending on cycle, or 4 weeks after nivolumab) if that is shorter.\n4. Has unresolved toxicities from previous anticancer therapy. Anticancer therapy toxicities are defined as toxicities (other than alopecia) not yet resolved according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 ≤ Grade 1, or baseline (participants with ≤ Grade 2 neuropathy may be eligible).\n\n   * Note: Patients in an LNS8801/pembrolizumab combination cohort must not have undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years. (Participants who have had a transplant greater than 5 years ago are eligible as long as there are no symptoms of acute graft versus host disease \\[GVHD\\])\n5. Patients must not be participating in another study of an investigational agent or have used an investigational device within 4 weeks before the first dose of study drug.\n\n   Note: Patients who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.\n6. Has a symptomatic primary central nervous system (CNS) tumor, symptomatic CNS metastases, leptomeningeal carcinomatosis, or untreated spinal cord compression.\n\n   Note: Patients are eligible if neurologic symptoms and CNS imaging are stable and steroid dose is stable for 14 days prior to the first dose of study drug and no CNS surgery or radiation has been performed for 28 days (14 days if stereotactic radiosurgery).\n\n   a. In a LNS8801/pembrolizumab combination cohorts, has known active CNS metastases and/or carcinomatous meningitis.\n7. Requires the use of antitumor necrosis factor (anti-TNF) therapies, such as infliximab, or has received treatment with anti-TNF therapies within 5 half-lives of that therapy.\n8. Has an active autoimmune disease that required systemic treatment in the past 2 years (ie, with use of disease-modifying antirheumatic agents or immunosuppressive drugs).\n\n   Note: Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal, thyroid, or pituitary insufficiency) is permitted.\n9. Has a diagnosis of immunodeficiency, is on immunosuppressive therapy, or is receiving chronic systemic or enteric steroid therapy (in dosing exceeding 10 mg/day of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n\n   Note: At screening, patients may be using systemic corticosteroids (dose 10 mg/day of prednisone or equivalent) or topical or inhaled corticosteroids.\n10. Is receiving any other investigational agent(s) or has received an investigational agent within 30 days or 5 half-lives, whichever is shorter, of the first dose of study drug.\n11. Has had major surgery (excluding placement of vascular access) within 4 weeks prior to the planned start of LNS8801.\n12. Has had radiotherapy with a limited field for palliation (less than 2 weeks) within 1 week of the first dose of study drug to non-CNS disease, with the exception of patients receiving radiation to more than 30% of the bone marrow or with a wide field of radiation, which must be completed at least 4 weeks prior to the first dose of study drug. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.\n13. Has evidence of pneumonitis or interstitial lung disease.\n\n    a. For pembrolizumab combination cohorts, has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis\n14. Has any of the following known infections:\n\n    1. Human immunodeficiency virus (HIV), hepatitis B virus (HBV) (ie, hepatitis B surface antigen-positive), or hepatitis C virus (HCV) (ie, detectable HCV ribonucleic acid \\[RNA\\]).\n\n       Note: Patients with a prior history of treated HBV infection who are antigen-negative or patients with a prior history of treated HCV infection who are HCV RNA-undetectable may be enrolled.\n    2. Active infections requiring systemic therapy (including asymptomatic infections with positive virus titers and the Investigator's judgment that worsening of the condition is likely with study drug or the condition would impair or prohibit a patient's participation in the study).\n15. Has active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug.\n16. Has received a live vaccine within 30 days of the planned start of study drug.\n17. Has a corrected QT interval (QTc) by Fridericia method \\>450 msec for male patients or \\>470 msec for female patients, or a history or risk factors for or use of medications known to prolong the QTc or that may be associated with torsades de pointes.\n\n    Note: Isolated right bundle branch block and incomplete right bundle branch block and left anterior hemiblock are acceptable.\n18. Has had any prior treatment for the present solid malignancy with GPER agonists (eg, tamoxifen, raloxifene, or estrogen hormone replacement therapy). History of oral contraceptive use is permissible.\n19. Is using a strong inhibitor or inducer of cytochrome P450 1A2, 2C9, 2C19, 2D6, or 3A4.\n20. Requires treatment with a proton pump inhibitor.\n21. Has received estrogen treatment since cancer diagnosis or the presumed initiation of their cancer, including estrogen-based contraceptives.\n22. Has a cancer that was treated with estrogen hormone therapy.\n23. Is currently using estrogen hormone replacement therapy, was diagnosed while on estrogen hormone replacement therapy, or has used estrogen replacement therapy since diagnosis.\n24. Is pregnant, lactating, has been pregnant within the last 2 years, or is planning to attempt to become pregnant or impregnate someone during this study or within 90 days after dosing of study drug (120 days for LNS8801/pembrolizumab combination cohorts).\n25. Has a history of another active malignancy (a second cancer) within the previous 2 years except for localized cancers that are not related to the current cancer being treated, are considered cured, and, in the opinion of the Investigator, presents a low risk of recurrence. These exceptions include, but are not limited to, basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.\n26. Has an uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, hypertension, unstable angina pectoris, cardiac arrhythmia, autoimmune or inflammatory diseases, or psychiatric illness/social situations that would limit compliance with study requirements.\n27. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n28. Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study in the medical judgement of the investigator.\n29. Has received radiation therapy to the lung that is \\>30 Gy within 6 months of the first dose of trial treatment for patients with non-small cell lung cancer.\n30. In the LNS8801/pembrolizumab combination cohorts, has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137), and was discontinued from that treatment due to a Grade 3 or higher irAE.\n31. Has had an allogenic tissue/solid organ transplant."", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Tina Garyantes, PhD', 'role': 'CONTACT', 'phone': '(908) 420-1159', 'email': 'tgaryantes@linnaeustx.com'}, {'name': 'Mackenzie Tseng-Lee, MBA', 'role': 'CONTACT', 'phone': '(513) 579-9911', 'phoneExt': '24120', 'email': 'm.tseng-lee@medpace.com'}], 'overallOfficials': [{'name': 'Tina Garyantes, PhD', 'affiliation': 'Linnaeus Therapeutics, Inc.', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Cedars-Sinai Medical Center', 'status': 'RECRUITING', 'city': 'Los Angeles', 'state': 'California', 'zip': '90048', 'country': 'United States', 'contacts': [{'name': 'Kari Kayser, RN, BSN, CCRP', 'role': 'CONTACT', 'phone': '(310) 967-0694', 'email': 'kari.kayser@cshs.org'}], 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'facility': 'Yale Cancer Center', 'status': 'RECRUITING', 'city': 'New Haven', 'state': 'Connecticut', 'zip': '06519', 'country': 'United States', 'contacts': [{'name': 'Trisha Burrello, MS,CCRC', 'role': 'CONTACT', 'phone': '203-464-5227', 'email': 'trisha.burrello@yale.edu'}, {'name': 'Ingrid palma, MHS', 'role': 'CONTACT', 'phone': '2037375342', 'email': 'ingrid.palma@yale.edu'}], 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'facility': 'Massachusetts General Hospital', 'status': 'RECRUITING', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02114', 'country': 'United States', 'contacts': [{'name': 'Jessica Jiyeong Lin', 'role': 'CONTACT', 'email': 'jjlin1@partners.org'}], 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'University of New Mexico Comprehensive Cancer Center', 'status': 'RECRUITING', 'city': 'Albuquerque', 'state': 'New Mexico', 'zip': '87106', 'country': 'United States', 'contacts': [{'name': 'Valerie Parks, RN,MSN', 'role': 'CONTACT', 'phone': '(505) 925-0390', 'email': 'vparks@salud.unm.edu'}, {'name': 'Carolyn Muller, MD', 'role': 'CONTACT', 'email': 'cmuller@salad.unm.edu'}], 'geoPoint': {'lat': 35.08449, 'lon': -106.65114}}, {'facility': 'Columbia University Herbert Irving Comprehensive Cancer Center', 'status': 'RECRUITING', 'city': 'New York', 'state': 'New York', 'zip': '10032', 'country': 'United States', 'contacts': [{'name': 'Samatha Petruzzelli, BS', 'role': 'CONTACT', 'phone': '212-305-3236', 'email': 'sp4099@cumc.columbia.edu'}], 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Memorial Sloan Kettering Cancer Center', 'status': 'RECRUITING', 'city': 'New York', 'state': 'New York', 'zip': '10065', 'country': 'United States', 'contacts': [{'name': 'Christopher Boutelle, BS', 'role': 'CONTACT', 'email': 'boutelc@mskcc.org'}], 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'University of Pennsylvania', 'status': 'RECRUITING', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'zip': '19106', 'country': 'United States', 'contacts': [{'name': 'Alexander Riccio', 'role': 'CONTACT', 'phone': '215-829-6117', 'email': 'alexander.riccio@pennmedicine.upenn.edu'}, {'name': 'Justine Cohen, MD', 'role': 'CONTACT', 'email': 'Justine.cohen@pennmedicine.upenn.edu'}], 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'facility': 'Thomas Jefferson University, Sidney Kimmel Cancer Center', 'status': 'RECRUITING', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'zip': '19107', 'country': 'United States', 'contacts': [{'name': 'Dennis Stone, MS', 'role': 'CONTACT', 'phone': '215-586-0199', 'email': 'askphase1@jefferson.edu'}, {'name': 'Traci Southwell, MSN, RN', 'role': 'CONTACT', 'email': 'Traci.Southwell@jefferson.edu'}], 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'facility': 'MD Anderson Cancer Center', 'status': 'RECRUITING', 'city': 'Houston', 'state': 'Texas', 'zip': '77030', 'country': 'United States', 'contacts': [{'name': 'Jordi Rodon, MD', 'role': 'CONTACT', 'phone': '713-563-1930', 'email': 'jrodon@mdanderson.org'}], 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'facility': 'The START Center for Cancer Care', 'status': 'RECRUITING', 'city': 'San Antonio', 'state': 'Texas', 'zip': '78229', 'country': 'United States', 'contacts': [{'name': 'Isabel Jimenez, RN, MSN', 'role': 'CONTACT', 'phone': '210-593-5265', 'email': 'isabel.jimenez@startsa.com'}], 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}]}}",,,"{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008545', 'term': 'Melanoma'}, {'id': 'D000098943', 'term': 'Uveal Melanoma'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}, {'id': 'D013274', 'term': 'Stomach Neoplasms'}], 'ancestors': [{'id': 'D018358', 'term': 'Neuroendocrine Tumors'}, {'id': 'D017599', 'term': 'Neuroectodermal Tumors'}, {'id': 'D009373', 'term': 'Neoplasms, Germ Cell and Embryonal'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D009380', 'term': 'Neoplasms, Nerve Tissue'}, {'id': 'D018326', 'term': 'Nevi and Melanomas'}, {'id': 'D012878', 'term': 'Skin Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D014604', 'term': 'Uveal Neoplasms'}, {'id': 'D005134', 'term': 'Eye Neoplasms'}, {'id': 'D005128', 'term': 'Eye Diseases'}, {'id': 'D014603', 'term': 'Uveal Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D013272', 'term': 'Stomach Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C582435', 'term': 'pembrolizumab'}]}}",False
"{'identificationModule': {'nctId': 'NCT06730477', 'orgStudyIdInfo': {'id': 'XHJY20240912'}, 'organization': {'fullName': 'Union Hospital, Tongji Medical College, Huazhong University of Science and Technology', 'class': 'OTHER'}, 'briefTitle': 'Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma', 'officialTitle': 'Based on Plasma Exosomes Combined With Multi-omics Analysis to Reveal the Trajectory of Targeted Therapy Resistance and Novel Target Intervention Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma'}, 'statusModule': {'statusVerifiedDate': '2024-12', 'overallStatus': 'ENROLLING_BY_INVITATION', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-01-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-12-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-12-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-09-12', 'studyFirstSubmitQcDate': '2024-12-11', 'studyFirstPostDateStruct': {'date': '2024-12-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-12-11', 'lastUpdatePostDateStruct': {'date': '2024-12-12', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Yang Jin', 'investigatorTitle': 'deputy dean', 'investigatorAffiliation': 'Union Hospital, Tongji Medical College, Huazhong University of Science and Technology'}, 'leadSponsor': {'name': 'Union Hospital, Tongji Medical College, Huazhong University of Science and Technology', 'class': 'OTHER'}, 'collaborators': [{'name': ""Yichang Central People's Hospital"", 'class': 'OTHER'}, {'name': 'Suizhou Hospital, Hubei University of Medicine', 'class': 'UNKNOWN'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The objective of this observational study is to explore the therapeutic trajectory of targeted therapy in lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutations. The main objective is to identify potential biomarkers that can predict the efficacy of targeted therapy through plasma exosomes and to explore strategies to reverse drug resistance to targeted therapy. Biological specimens and medical imaging data will be collected from patients already receiving targeted therapy as a first-line treatment, and followed-up will be conducted to analyze prognosis based on different patterns.', 'detailedDescription': 'The medical imaging data will be collected retrospectively and prospectively, and the blood samples and tumor tissues will be collected prospectively.'}, 'conditionsModule': {'conditions': ['Lung Adenocarcinoma', 'EGFR Activating Mutation']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'OTHER'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Blood samples and tumor tissues will be retained'}, 'enrollmentInfo': {'count': 500, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Untreated EGFR mutated lung adenocarcinoma patients', 'description': 'Patients diagnosed with lung adenocarcinoma with EGFR mutations for the first time.', 'interventionNames': ['Other: observational study']}, {'label': 'Patients with EGFR-mutated lung adenocarcinoma who are responding to targeted therapy', 'description': 'Patients with EGFR-mutated lung adenocarcinoma treated with targeted therapy combined with or without chemotherapy as first-line therapy, and the therapeutic effect was in the response stage.', 'interventionNames': ['Other: observational study']}, {'label': 'Patients with EGFR-mutated lung adenocarcinoma who are resistant to targeted therapy', 'description': 'Patients with EGFR-mutated lung adenocarcinoma treated with targeted therapy combined with or without chemotherapy as first-line therapy, and the therapeutic effect was in drug resistance stage, or disease progression.', 'interventionNames': ['Other: observational study']}], 'interventions': [{'type': 'OTHER', 'name': 'observational study', 'description': 'Efficacy of targeted therapy combined with or without chemotherapy as first-line therapy in patients with EGFR-mutated lung adenocarcinoma.', 'armGroupLabels': ['Patients with EGFR-mutated lung adenocarcinoma who are resistant to targeted therapy', 'Patients with EGFR-mutated lung adenocarcinoma who are responding to targeted therapy', 'Untreated EGFR mutated lung adenocarcinoma patients']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'progression-free survival', 'description': 'The time of disease progression is evaluated according to the Response Evaluation Criteria in Solid Tumors, version 1.1.', 'timeFrame': 'A two-year period after starting treatment (Regular follow-up every three months after receiving targeted therapy combined with or without chemotherapy as first-line treatment)'}], 'secondaryOutcomes': [{'measure': 'Overall survival', 'description': 'The survival time after receiving targeted therapy combined with or without chemotherapy as first-line treatment', 'timeFrame': 'A three-year period after starting treatment (Regular follow-up every six months after receiving targeted therapy combined with or without chemotherapy as first-line treatment)'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* Pathological examination confirmed lung adenocarcinoma\n* No other type of tumor was present\n* Common sensitive EGFR (Ex19Del L858R or combined with other sites) mutations have been identified\n* Receive targeted therapy with or without chemotherapy as first-line treatment\n* ≥ 18 years and ≤80 years old\n\nExclusion Criteria:\n\n* History of other malignant tumors\n* Irregular treatment or poor compliance\n* Incomplete clinical information or lost to follow-up', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'From January 2021 to December 2026, about 500 patients with EGFR-mutated lung adenocarcinoma who receive targeted therapy with or without chemotherapy as first-line treatment will be included in this cohort study', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'locations': [{'facility': 'Union hospital, Tongji Medical college, Huazhong University of Science and Technology', 'city': 'Wuhan', 'state': 'Hubei', 'zip': '430022', 'country': 'China', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}",,,"{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000077192', 'term': 'Adenocarcinoma of Lung'}], 'ancestors': [{'id': 'D000230', 'term': 'Adenocarcinoma'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D019370', 'term': 'Observation'}], 'ancestors': [{'id': 'D008722', 'term': 'Methods'}, {'id': 'D008919', 'term': 'Investigative Techniques'}]}}",False
